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The specter of Human Immunodeficiency Virus (HIV) or Acquired Immune Deficiency
Syndrome (AIDS) has become increasingly prevalent since it first entered public
awareness in 1982. The Center for Disease Control (CDC) estimates that approximately 1
million people in the United States of America (USA) are living with HIV/ AIDS. More
alarming is the fact that approximately 250,000 people remain unaware of their
seropositivity status, therefore putting themselves and others at risk. Ignorance
concerning HIV status is due largely to two factors: either failure to take an HIV test in
the first place, or, a failure to retrieve results after testing. Despite the distinct possibility
that anxiety plays a role in decisions concerning HIV testing an extensive literature
review yielded no study that specifically examined the association between anxiety and
HIV testing behavior. Thus, the purpose of the study was to determine the influence of
anxiety, both general and specific, on prospective HIV testing behavior. The design of the
study was correlational, examining how a group of independent variables (namely,
various types of anxiety) impact two separate dependent variables (likelihood of being
tested HIV and likelihood of returning for results of the HIV test results). Three hundred
and forty seven participants were administered measures assessing anxiety, both at the
broad or "global" level and at the narrower level of context-specific or domain-relevant
anxiety. Each participant completed the State-Trait Anxiety Inventory (STAI), Self-Rated

Anxiety Scale (SAS), Subscales of the Medical Anxiety Scale (MAS), Death Anxiety
Scale (DAS), and the Multidimensional AIDS Anxiety Questionnaire (MAAQ). A
stepwise multiple regression data analytic strategy was used to examine the data.
Analyses suggested that AIDS-Specific Anxiety accounted for a significant amount of
variance in the independent variable of the Likelihood of Receiving HIV Testing and that
Hospital and X-Ray Anxiety, respectively, accounted for a significant amount of variance
in the independent variable of Likelihood of Returning to Receive the Results of HIV
Testing; however, variance attributed to each of the dependent variables that remained
after stepwise regression, was low. Once the researchers controlled for extraneous
variables such as the relevant demographic variables of gender, ethnicity, previous HIV
testing history, past sexual history, and relationship status, the variables that had been
retained in both the equations - AIDS-Specific Anxiety and Hospital and X-Ray Anxiety,
respectively - no longer accounted for a significant amount of variance and none of the
variables assessed in the study were retained in the models examining the influence of
anxiety on Likelihood to Receive HIV Testing and Likelihood of Returning for HIV
Testing Results. Although the current study did not yield the anticipated results, the
findings contribute to research concerning the influence of personality variable on disease
status. The findings presented here may present researchers with a starting point for
further empirical endeavors. Considering the limitations of the study and applying the
suggestions derived from frankly addressing those limitations, future research may
indeed reveal a significant impact of anxiety on HIV testing behavior.
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Review of Literature
Acquired Immune Deficiency Syndrome (AIDS) has become, without a doubt, an
international epidemic due to its worldwide prevalence. Even in light of evidence
suggesting a "success in controlling the epidemic in some countries, and a decline in
prevalence in others, AIDS is still the single most important health crisis the world faces"
(Poku & Whiteside, 2006, p. 250). As Spearman (2006) notes, despite the exertion of
considerable effort of the international medical community to develop a preventative
vaccine, twenty years have passed and still no Human Immunodeficiency Virus (HIV)
vaccine is available.
Global Estimates (UNAIDS & World Health Organization [WHO], 2005) provide
a numerical index of the magnitude of this problem. In 2005, 40.3 million individuals
were estimated to be living with HIV/AIDS. Of these individuals approximately 38
million of the infected individuals were adults (aged 15 to 49), and 2.3 million were
children (aged under 15). In the United States of America (USA), the Center for Disease
Control (CDC) estimated that at the end of 2003, between 1,039,000 to 1,185,000
persons in the USA were living with this disease (CDC, 2004a). The CDC (2005)
highlights several advances that have been made in an attempt to curb the growing
number of people affected by the disease. Advances in fighting the disease include
reductions in mother-to-child transmission; drug combinations that treat and delay the
onset of AIDS; increased community level involvement in prevention efforts; better
understanding of high risk communities as well as the implementation of several
behavioral interventions. However, these successes are overshadowed by the fact that in
the USA about 1 million people are living with HIV or AIDS. The more alarming number
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is the approximately 250,000 people who are unaware of their infection, therefore putting
themselves and others at risk. "Those who do not know that they are infected cannot take
advantage of treatment and may unknowingly transmit HIV to others" (CDC, 2005, p.
19). Among the prevention strategies suggested by the CDC is the promotion of early
diagnosis of HIV, which entails nothing more than taking an HIV test to determine one's
status. However, as noted above, many seropositive individuals remain unaware of their
status. This ignorance concerning status is due to two factors, either these individuals
have failed to take a test, or they have taken a test but failed to retrieve their results.
A body of research has attempted to examine the reasons behind the failure to
return for the results of HIV testing (Dinh, Detels, & Nguyen, 2005; Hightow et al., 2003;
Strauss, Deren, Rindskopf & Falkin, 2002; Sullivan, Lansky & Drake, 2004) as well as
the reasons that lead individuals either to seek out or avoid HIV testing (Lyter, Valdiserri,
Kingsley, Amoroso & Rinaldo, 1987; Riess, Kim & Downing, 2001). It is purpose of the
present study to evaluate the causes of testing avoidance, as well as the failure to return
for HIV test results, by specifically examining the role of anxiety and various defense
mechanisms in attitudes towards HIV testing and the results of HIV testing.
HIV/AIDS
The question arises as to why AIDS, as a public health threat and a disease,
appears to be viewed as such a special case. Kiemle (1994) states that it is a result both of
the heightened awareness that appears to accompany it and because it causes the loss of
life and the investment of considerable money and resources. The author argues that the
uniqueness of AIDS lies in several factors such as that it not only affects those who
contract it on a biological level, but also on a profoundly emotional level as well;
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moreover, the disease affects not only the sufferer, but also places a heavy load on the
direct family of the sufferer, his or her significant others, as well as counselors, and
society at large. Furthermore, the disease indiscriminately affects both young and old
alike. The subject of AIDS combines many taboos such as sex and sexuality, disease,
disability, death and dying; and AIDS holds a special status because it often elicits the
overt stigmatizing of, and discrimination against, those with the disease. Moreover, AIDS
provokes more anxiety and notice because it is incurable and prospects for a vaccine to
combat it remain bleak (Kiemle, 1994). Although current research is ambiguous with
regards to the exact origin and even the first reports of the disease, the following history
is most often suggested. Prior to July 1982, AIDS consisted of nothing more than a few
cases of a medically bizarre and an as-yet-unnamed complex of often rare diseases found
in homosexuals and hunters in Western-Central Africa. The status of the disease changed
irrevocably in 1982 when the term AIDS was coined and a 20-month-old child died from
an AIDS-related infection contracted through a blood transfusion, at last providing a clear
sign that the transmission of AIDS was not limited exclusively to homosexual contact.
During the twenty-five years that have intervened between its discovery and the present
date, scientific research has determined the virus that causes AIDS is HIV (Hutchinson,
2001; Mayer, 2005; Moore, 2004; Morrow, Isenberg, Sobol, Strieker, & Kieber-Emmons,
1991; Watts, Okello, & Watts, 1990)
While a discussion of the mechanism of the disease is beyond the scope of the
present study, AIDS, in brief, is a disease in which HIV significantly compromises the
body's immune system. In order to understand HIV/AIDS it is important first to
understand the working of the human immune system. In a healthy individual the

4

immune systems helps to identify and eliminate antigens: foreign materials or substances
such as bacteria, viruses, and parasites. Additionally, the immune system also targets the
individual's own cells that have become damaged in some way. The foundation of the
immune system lies in specific types of cells that are at work, with white blood cells or
leukocytes being the most prominent. Macrophages, a type of leukocyte are the body's
first line of defense, surrounding the identified antigens and destroying them.
Macrophages also serve another important purpose, signaling lymphocytes, which consist
of two main groups, B and T cells. B cells function within the humoral branch of the
immune system, releasing molecules that find and neutralize antigens. Immunoglobulin is
produced and functions as an antibody and when it interacts with the antigen neutralizes
it. When the task is completed, it creates memory B cells that remember the antigen; thus,
the next time the antigen is introduced into the body, the immune system will respond
much faster. T cells operate in the cellular branch of the immune system and instead of
creating antibodies like B cells; a subgroup of T cells called killer T cells directly
destroys the antigens. Another subgroup of T cells, called helper T cells, signals B cells
to produce antibodies as well as signaling other T cells to destroy antigens. Yet another
subgroup of T cells is called suppressor T cells; these function to suppress the production
of antibodies by B cells when they are no longer needed. A very unique interaction
between the humoral and cellular branch of the immune system is facilitated by all of
these T cells. HIV ravages the immune system by directly and indirectly targeting and
attacking the T cells (specifically CD4+ T cells), dendritic cells, as well as macrophages.
The CDC's classification system stipulates that when a person's CD4+ T cell count falls
below 200 per microliter (p.1) blood, that person's cellular immunity is damaged to the

5

extent of it leading to AIDS. Generally, healthy people have between 500 and 1500
CD4+ T cells per

(Barlow & Durand, 2001; CDC, 1993; Hutchinson, 2001; Kalat,

2000; Margolick et al., 1998; Nowak & McMichael, 1995).
The immunological weakening consequent to the HIV infection then leads to an
increased risk of contracting a variety of fatal diseases such as Kaposi's sarcoma (KS),
Pneumocystis jiroveci pneumonia (Formerly known as Pneumocystis carinii pneumonia
or PCP), Tuberculosis, Toxoplasmosis, AIDS dementia complex, as well as a variety of
dangerous fungal, viral, parasitic and bacterial infections. Most of these illnesses are
termed as opportunistic, because they take advantage of the opportunity of a weakened
immune system to attack. In individuals with a normal and healthy immune system, these
conditions and infections are usually kept under control by the very elements of the
immune system that are weakened and damaged by HIV. Technically a person does not
die from AIDS but rather a disease or infection contracted because of the vulnerability
resulting from the disease (Barlow & Durand, 2001; Davison, Kring & Neale, 2004;
Kaplan & Sadock, 1998; Leigh, Shetty, & Fidel, 2004). The World Health Organization
(WHO), in 1990, grouped these infections and conditions together in such a manner as to
create a system that can be utilized to identify the stage in which an individual infected
with HIV-1 is likely to be. These stages range from Stage I (in which the HIV disease is
asymptomatic and not yet classified as AIDS) through to Stage V (in which the patient is
likely to have toxoplasmosis of the brain, candidiasis of the esophagus, trachea, bronchi
or lungs as well as Kaposi's sarcoma) (WHO, 1990).
After the individual is infected with HIV, it is expected that a person will develop
AIDS between 7.3 to 10 years later. The course of the disease varies with several minor
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health problems starting to develop. Emergence of symptoms occurs anywhere between
several months and several years after HIV was contracted. The condition, AIDS-related
complex (ARC), consists of these minor problems such as fever, weight loss, and night
sweats. AIDS is not diagnosed until one of the aforementioned serious opportunistic
diseases appears. The expected median survival time after developing AIDS is 9.2
months, although survival time is significantly increased in those cases where the
individual undergoes antiretroviral therapy, to as much as 5 years (Morgan et al., 2002;
Schneider et al., 2005).
It is also important to note that various types of HIV have been identified. In
humans, two types of HIV are known. HIV-1 is considered the most prevalent with HIV2 linked with most cases in West Africa and India (Hutchinson, 2001). Each HIV cell
has a genetic structure, which differs for the two types. Furthermore, during the
replication of the HIV cell, certain mistakes can be made, leading to mutations of the
original cell. In some instances, these mutated cells are inactive copies; however others
may be HIV mutants that have an enhanced survival and/ or replication ability. These
cells become worrisome, as their transmission to other individuals and further mutations
could ultimately lead to a new viral strain such as HIV-3 (Stine as cited in Hutchinson,
2001). Furthermore, based on the genetic structures of the HIV cells, researchers have
been able to identify subtypes. Within the HIV-1 strain, three subtypes are identified: M,
N, and O. Each of these subtypes can even farther be divided into categories. Group M is
considered the most prevalent and is further divided into 9 categories or clades, noted as
A through I (Hutchinson, 2001; Thomson, Perez-Alvarez & Najera, 2002). Of these,
clades A, B, and C represent the large majority, approximately 86%, of circulating HIV-1
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variants with B being the most prevalent in Europe, Brazil, Canada, Australia, Haiti, and
the USA, as well as in South African men who have sex with men (Coplan et al., 2005).
This information is of most importance when considering the type of HIV testing an
individual needs to undergo. For example, due to very low prevalence rate of the HIV-2
strain within the USA (as indicated by epidemiologic data), the CDC (2002) does not
recommend routine HIV-2 testing, however, in the instance that an individual's HIV test
returns with a positive screening for HIV, the site will test for both HIV-1 and HIV-2
strains in the case that epidemiologic risk factors for HIV-2 are present. Furthermore,
testing for HIV-2 will be conducted if clinical evidence exists for HIV, in the absence of
a positive test for antibodies to HIV-1, or if the HIV-1 Western blot test exhibits an
unusual pattern (O'Brien, George, Epstein, Holmberg, & Schochetman, 1992).
Additionally, since 1992, the Food and Drug Administration (FDA) have required that all
donated blood be screened for HIV-2 (O'Brien et al., 1992).
Most often, HIV is transmitted from one individual to another though sexual
intercourse, but it is readily transmitted via contact with infected blood (e.g., through
blood transfusion). Unprotected anal and vaginal sex and intravenous drug use are
considered the most risky behaviors associated with HIV transmission. The CDC (2004a)
breaks down the estimated number of cases diagnosed according to transmission category
(Table 1).
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Table 1
Estimated numbers of cases of HIV/AIDS, by year of diagnosis, population and
transmission

category.
Year of diagnosis
2001

2002

2003

2004

Male-to-male sexual contact

16,625

16,852

16,804

18,203

Injection drug use

5,171

4,379

4,177

3,828

1,525

1,431

1,398

1,372

Heterosexual contact

5,095

4,843

4,720

4,581

Other

214

183

179

161

Injection drug use

2,877

2,408

2,252

2,134

Heterosexual contact

9,192

8,709

8,248

8,102

Other

211

187

205

174

Perinatal

306

245

186

145

Other

54

44

18

32

Total

41,270

39,280

38,188

38,730

Male adult or adolescent

Male-to-male sexual contact
and injection drug use

Female adult or adolescent

Child (<13 years at diagnosis)

Based on statistics concerning the transmission of AIDS in the USA, the
frequency of the various means of transmission in 2004 is the following: 43% of cases
were contracted by male-to-male sexual contact; 25% contracted by injection drug use;
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25% contracted by heterosexual contact; and, the remainder through male-to-male sexual
contact and injection drug use, hemophilia, blood transfusion, perinatal, and risk factors
not reported or not identified (CDC, 2004a).
Using confidential name-based HIV infection reporting, the CDC (2004a) breaks
down the estimated number of cases diagnosed, deaths associated to AIDS, and
individuals living with AIDS in the USA's 35 areas. Table 2 lists these estimated
numbers accordingly for the years 2000 until 2004.
Table 2
Estimated numbers of new diagnosis of HIV/AIDS, AIDS related deaths and individuals
living with AIDS, by year.
Year
2000

2001

2002

2003

2004

AIDS diagnoses

39,513

39,060

40,670

41,831

42,514

AIDS deaths

17,139

17,611

17,544

17,849

15,798

320,177

341,773

364,496

388,477

415,193

Individuals living
with AIDS

Based on tracking by the CDC, there was an 8% decrease in the estimated number
of AIDS deaths from 2000 to 2004; during the same time frame; however, the number of
cases of individuals diagnosed with AIDS increased 8% (CDC, 2004a). Approximately
40,000 persons become infected every year when one considers all 50 states (Glynn and
Rhodes, 2005). The increased number of individuals living with AIDS in the USA is
attributed to the fact that better treatments are available and there has been an increase in
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the use of intensive antiretroviral therapies (Palella et al., 1998; Schneider et al., 2005).
When one considers the anonymous, almost unobtrusive origins of AIDS in the early
1980s, it appears that the cases of the disease occurring in seemingly isolated segments of
society have transformed into one of the major threats to global health.
HIV Testing
HIV tests are used to detect antibodies and antigens, as well as ribonucleic acid
(RNA) in various specimens (serum, blood plasma, oral fluid, dried blood spot or urine).
In the USA the initial test used to detect the presence of antibodies, the cells created in a
response to the infection, is the Enzyme-Linked Immunosorbent Assay (ELISA) method.
In the event that this initial test detects antibodies, a second test, based on the Western
Blot method, is utilized. The antibody test is then reported as either being positive or
negative. The performance of these tests is described by considering the test's sensitivity
(the percentage of results that are positive when HIV is present) as well as its specificity
(the percentage of the results that are negative when HIV is not present). In the USA, this
two-test approach is used, claiming to have a 99.5% accuracy rate, which translates into
500 false positive results (result indicating HIV is present, when it is not) for every
100,000 people not infected with HIV who are tested. False negative results (result
failing to indicate HIV when it is present) are most common during the window period,
or the time between when the infection occurs and the test can first detect a change in the
body. Antibody tests have an average window period of 22 days. (US Food and Drug
Administration [FDA], 2006)
Antigen testing decreases the window period to about 16 days. This method is
routinely used to screen blood donations; however it is not utilized otherwise for
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diagnostic purposes as it has a very low sensitivity and is only reliable during a specific
time: before antibodies are produced by the body. Since 2001, Nucleic Acid based testing
has become the preferred testing method for blood donations, as it shortens the window
period to 12 days. Although this method is relatively expensive, a version of it is used for
the clinical management of HIV infected patients.
Currently, several different tests for HIV have been approved by the Food and
Drug Administration (FDA) of the USA's government. The tests differ on the type of
specimen that is needed to perform the test, such as plasma, a dried blood spot, serum,
oral fluid, whole blood (venipunctured and fmgerstick), or urine. Additionally, these tests
vary based on the complexity of the test, the strains of HIV it can detect, and the time it
takes for the results to become available. Table 3 lists the various types of HIV tests that
have gained FDA approval (CDC, 2001; FDA, 2006).
Table 3
FDA approved HIV tests

Specimen

Test

collected

complexity

results available

High

few days

Standard HIV test

Serum or plasma

Rapid Tests

Serum, plasma,

Moderate

Time before

10-60 min

whole blood
Home sample collection

Dried blood spot

High

Oral fluid test

Oral Mucosal Transudate High

1 -2 weeks

Urine based

Urine

1-2 weeks

High

3-7 days
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Researchers are continuously attempting to expand on the ELISA as well as
Western Blot testing methods and, by doing so, add to the list of FDA approved HIV
tests. A recent addition to the repertoire of HIV tests is the rapid tests. Four rapid tests are
currently approved by the FDA: Oraquick Rapid HIV-1, Uni-Gold Recombigen HIV test,
Multispot HIV-1 /HIV-2 Rapid Test and Reveal Rapid HIV-1 antibody test, with two
being approved for point-of-care sites without a traditional laboratory (FDA, 2006;
Greenwald, Burnstein, Pincus, & Branson, 2005). Most noticeable is the approval of
rapid tests with oral fluid. These tests require a specimen of the individual's oral fluid,
taken by gently swabbing all around both the upper and bottom gums. One example is the
OraQuick Rapid HIV test for oral fluid, which was approved in 2004, research indicating
a 99.3% sensitivity and 99.8 % specificity. However, rapid testing can also be performed
on other specimens such as whole blood, plasma or serum (CDC, 2004b).
Although these tests are generally less invasive and results are available in less
than 20 minutes, in the cases where the client has a reactive test result (indicating an HIV
positive status), a second confirming test, taking approximately 7 to 10 days, will still
need to be done (Liang et al., 2005). Liang et al. (2005) found that among 461 clients
tested at a mobile STD/ HIV clinic, 64.5% preferred OraQuick to traditional serologic
testing. Notably, however, the clients were not surveyed as to the reason they made their
choice of a particular HIV test. Poses (as cited in Kane, 1999) points out that a division
has emerged in the field as concerns the use of rapid testing because, while some clients
will within minutes be correctly informed of their HIV status, others may experience
unnecessary anxiety due to false positive results. On the other hand, rapid testing
increases the number of people who are aware of their true HIV status by giving them
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feedback before they return home and is of particular benefit in situations of potential
occupational exposure to HIV (Kane, 1999). Greenwald et al. (2006) argues that when
rapid testing is compared to standard two-session HIV-testing, rapid HIV testing both
decreases costs and increases the number of people receiving their results.
Home testing is another recent trend in HIV testing. The FDA approved the first
home test kit in 1996, and these can be purchased in some drug stores, over the Internet,
or by mail. These tests require that the individual draw his or her own blood sample by
means of a finger prick at home, mail the sample to a laboratory, and call for the results
approximately 7 to 10 days later (Worthington, 2001). A study by Colfax et al. (2002)
indicated that despite the manufacturer's anticipation that a large amount of individuals
would utilize this testing method, the overall sales of home-based kits was relatively low,
representing approximately 1% of the HIV test performance in the USA that year.
Individuals who were aware of the tests availability cited concerns about accuracy, lack
of in-person counseling, and cost as reasons for not using this method (Colfax et al.,
2002). When considering the use of rapid testing it is noteworthy to cite the influence of
utilizing this method of testing in order to curb the frequency of individuals who fail to
return for their HIV test results. Keenan and Keenan (2001) suggested that by using rapid
testing it ensured that same-day results were given to all but one of the individuals tested,
resulting in a 0.1% failure to return rate. A study by Sullivan et al. (2004) also indicated
that the availability of rapid testing significantly reduced the failure to return.
HIV Testing Behavior
Taking into consideration the shockingly large number of AIDS cases worldwide,
a potentially more alarming fact is the sheer amount of individuals who either have never
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had their HIV status tested or who have been tested and failed to return for their results.
Janssen et al. (2001) estimated that approximately one third of the USA's residents who
are currently infected by HIV are unaware of their seropositive status, stating therefore
that an approach to reducing HIV incidence in the USA would be to increase the number
of HIV-infected persons who are aware of their serostatus, thereby creating an
opportunity for their adoption of behaviors limiting the probability of HIV transmission
to others (Janssen et al., 2001). In a study that included 512 individuals who received
HIV testing, Hightow et al. (2003) found that nearly 55% of people in the sample failed
to return to determine their HIV status and 58% of the non-returning individuals were
HIV positive. Furthermore, the study indicated that it took a median of 12 days for
disease intervention specialists to locate the infected individuals. Similar results were
reported by Dinh et al. (2005) in a study of 500 pregnant women in Vietnam, which
indicated that only 53.2% accepted HIV testing when offered and, of those, only 55.3%
returned for their results.
A national quantification of these behaviors can be seen when considering data
from the approximately 2.5 million HIV tests that are administered each year in the USA,
indicating that a staggering amount of individuals failed to return for their results.
Furthermore, of those individuals who failed to return for their HIV test results, 25% had
tested positive and 33% tested negative (Anderson, Chandra, & Mosher, 2005).
Considering the area from which participants for this study will be recruited, a discussion
of the incidence of germane HIV-testing relevant behaviors is warranted. Aggregate
figures indicate that 41% of the individuals tested, failed to return for their results
(Kentucky Department for Public Health, HIV/AIDS Branch, 2006).
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Regarding the greater community around Western Kentucky University (WKU)
information on HIV testing behavior was obtained from Carrie Halcomb, the Health
Educator of the Community Health Promotion Team 1 from Barren River District Health
Department in Bowling Green, KY. According to Ms. Halcomb, in Warren County, one
in 3 individuals who tested positive for HIV failed to return for their results, and
statewide 16% of the individuals who tested positive failed to return to learn their result.
The return rates for 2005 for the city of Bowling Green Kentucky indicate that nearly
two-thirds - fully 64% - of the individuals tested for HIV at the Warren County Health
Department failed to return to the facility to learn their test results (Halcomb, personal
communication, December 11, 2006).
In an interview with the Coordinator of Health Education at the WKU Health
Services, Kathryn Steward (personal communication, June 20, 2006) explained the
various HIV testing possibilities for WKU students offered by WKU Health Services.
WKU students are able to participate in anonymous HIV testing on one of three days
throughout the school year, during 'Health Day,' 'Sexual Awareness Week' and/or
'World AIDS Day.' While no official data on these events are collected, it is estimated
that approximately 40 to 50 students got tested for HIV at each event. Furthermore, Ms.
Steward estimates that only approximately 20% of those who take an HIV test return to
receive the results. She attributes this low return rate to two factors: the high number of
students who participate merely to receive extra credit and the possibility that
participating students misunderstand the testing situation. Anonymous testing is done in
such a manner that no identifying information is received from the participant. The
student is issued a number that coincides with his or her oral test sample. If the student
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wishes to know his or her results, he or she has to inquire from the appropriate person
following the HIV test and present the assigned number in order to receive testing results.
However, some students may fail to realize that it is their responsibility to follow-up on
the results and assume that if they do not hear from anyone, their HIV test results are
negative. Students are also able to get tested for HIV status, at their convenience, at the
student health services during usual operating hours. The test is confidential in nature, but
students have to request specifically to take the test from the physician. The student then
needs to be seen for post HIV-test counseling in order to receive the results.
From the above mentioned statistics, it appears that regardless of the geographical
region, the failure to return for HIV test results occurs far more often than those
endeavoring to prevent the spread HIV would desire. A better understanding of attitudes
related to HIV testing and the results of such testing might be useful in increasing the
number of individuals who return for the results of serological status testing or the
number of individuals who take an HIV test in the first place.
One possible explanation for the exceptionally high rates of individuals who fail
to return for the results of their HIV testing (or conversely the relatively low rates of
individuals who get tested in the first place) may be found in the study of avoidance
behavior. It is likely that the individuals who fail to take an HIV test or fail to return for
the results are either intentionally or unintentionally avoiding being faced with
information concerning their personal HIV status. When one initially considers avoidance
learning, it appears that nothing - that is no explicit contingency - acts as reinforcement
for a behavior, i.e. a person will continue to do a behavior without tangible reinforcement
of the behavior. However, one way to resolve the lack of explicit reinforcement in
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avoidance learning is via a consideration of Mowrer's two-factor theory (Barlow, 2004;
Klein, 2002; Mowrer, 1947; Mowrer, 1950; Terry, 2006). Mowrer argues that, in
avoidance learning, a person is not merely behaving because of "nothing"; rather the
reinforcer is an unobservable thing, i.e. the escape from an acquired fear or negative
reinforcement. Since avoidance behavior is integral to the discussion of anxiety
(particularly phobic manifestations of anxiety) there follows an in-depth discussion of
anxiety and the potential role it may play in HIV testing-related behaviors.
Anxiety
The experience of anxiety is considered to be fairly universal; everyone at some
point in time has been anxious. As a consequence, definitions of anxiety abound. The
pattern of arousal inherent in anxiety, however, can be defined in terms of psychological,
physiological as well as behavioral terms. Cannon (1927) coined the flight-or-fight
response: a physiological reaction to a threat, mediated by the sympathetic division of the
Autonomic Nervous System, that mobilizes a person to either fight or flee from an
emerging threat. This state is usually accompanied by physical reactions such as
increased heart rate, blood pressure and breathing, muscle tension and sweating; this
same pattern of arousal is seen in the individual expression of anxiety. Both human and
animal research indicates that the physical symptoms associated with the state of anxiety
are linked to activity in the central periaqueductal gray and medial hypothalamus, with
descending control from the amygdala. Physiological changes of arousal are implicated in
the overt behavioral manifestations of anxiety; sympathetic activation, for example, is
involved in such observable behaviors as attack posturing, escape maneuvers, active
avoidance, and even freezing in the presence of anxiety provoking stimuli, whether

internally or externally cued (Barlow, 2004; Barlow & Durand, 2001; Bourne, 2000;
Cannon, 1927; Davison, Kring & Neale, 2004; Kalat, 2000; Kaplan & Sadock, 1998).
Psychologically the experience of anxiety is more difficult to pin down with
exactitude. When trying to define anxiety most texts also define fear. Although it might
seem easy to distinguish between fear and anxiety, the distinction between fear and
anxiety based on the focus of threat or anxiety provoking stimulus can become blurred.
Several similarities exist between anxiety and fear such as the fact that both include an
elevated arousal and negative affect usually accompanied by bodily sensations and both
are a future oriented apprehensiveness about a danger or discomfort. Despite the
similarities, anxiety and fear can be differentiated (Rachman, 2004). The distinction
between fear and anxiety arose quite by accident when one of Freud's early translators
mistranslated the word Angst, the German word for fear, as anxiety. Strictly speaking, the
term fear refers to an individual's emotional reaction towards a specific, identifiable
object. Anxiety, on the other hand, is a more unsettling emotional reaction to the
anticipation of a vague, potential threat. Freud failed to put much emphasis on
distinguishing fear from anxiety. For Freud, anxiety was related more to an internal,
unknown object, whereas fear could be due to a repressed, unconscious conflict,
displaced onto an external object. The latter is best depicted in Freud's discussion of the
case of Little Hans, who "refused to go out on into the street because he was afraid of
horses" (Freud, 1959, p. 27). Freud had a theory that the little boy's fear of horses was a
displaced fear of his father; that is, even though there was an identifiable threat that
caused Little Hans' fears (i.e. the horse), it was not the object per se but rather an internal
Oedipal conflict that gave rise to the child's anxiety. In 1926, with the publication of
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"Inhibitions, Symptoms, and Anxiety," Freud created a new theory of anxiety. He no
longer regarded anxiety as resulting from an increased libido or a repressed thought or
wish, but rather as a reaction to dangerous situations. He went further to identify two
anxiety-provoking situations, the first involving an overwhelming instinctual stimulation,
as is found during the experience of birth. The second and more common type of anxiety
resulted from the anticipation of danger or a traumatic event (Freud, 1959; Barlow,
2004).
Modern conceptualizations differ greatly from Freud's attempts to explain anxiety
and fear. Behavioral theories focus on various types of learning, and the role these play in
acquiring fears. According to most behaviorally based theories, fear is considered to be a
conditioned response to a specific environmental stimulus (Kaplan & Sadock, 1998).
Watson and Rayner (1920) demonstrated a classical conditioning approach in their
experiment with Little Albert, in which a toddler was conditioned to fear white rats by
pairing a neutral stimulus (the white rat) with an unpleasant experience (a loud and
aversive noise). Furthermore, experiments in vicarious learning, or learning by
modeling, strongly suggest that phobic anxiety can be acquired by watching the reactions
of others to a given stimulus. Cognitive theorists, on the other hand, view anxiety and
fear as being related to an individual's thought processes. Accordingly, it is a person's
interpretations of a stimulus that can create the anxiety (Davison, Kring, & Neale, 2004).
Beck and Clark (1997), for instance, argued that automatic thoughts about the threat,
which arrived from distorted informational processing, trigger the components of the
anxiety response, consequently creating the state of anxiety.
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Despite the terminological confusion and the varied emphases of the different
theoretical conceptualizations of the origins of fear and anxiety, one fact remains: anxiety
is a virtually universal experience. It is generally agreed upon that, without some level of
anxiety, people would probably accomplish very little. The presence of a degree of
anxiety is considered to be a positive motivational factor in that it provides impetus for
physical and intellectual performances (Barlow, 2004; Davison, Kring & Neale, 2004;
Klein, 2002; Yerkes & Dodson, 1908). However, when anxiety is experienced in its
extreme form, in either its absence or at too great a level, the experience becomes
abnormal, causing the emergence of an anxiety disorder.
Two-factor Theory of Anxiety. The rise of behavioral therapy during the 1950 and
60's and the successes of specific behavioral techniques in the treatment of those with
phobias awakened an interest in the ways in which learning processes, such as
conditioning, were involved in the acquisition of anxiety. The earliest paradigm of
learning processes in the development of anxiety was best exemplified by Watson and
Rayner's conditioning of the fear of a white rat in Little Albert; needless to say, this
illumination of a learned fear focused exclusively on classical conditioning (Barlow,
2004; Klein, 2002; Watson & Rayner, 1920).
Mowrer in 1947, proposed the "two-factor theory," a modification of anxiety
acquisition that extended beyond simple classical conditioning. The two-factor theory
uses classical conditioning to argue that avoidance is really just an escape from an
acquired fear of a specific warning stimulus. Mowrer suggested that a warning stimulus
might be regarded as a conditioned stimulus because of its relation to an unpleasant event
that an organism later wants to avoid, but which is at first administered together. The
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warning stimulus then produces fear, which may be seen as a classically conditioned
response (or affective state) or can be seen in light of physical behaviors associated with
the activation of the autonomic nervous system. Reinforcement occurs when the
instrumental response reduces the fear by terminating the warning stimulus. So actually,
avoidance behavior is an escape response moved forward in time. The subject may be
regarded as escaping from the fear created by the warning stimulus rather than from the
unpleasant event that it has learned to fear (Klein, 2002; Terry, 2006).
When considering the role of the two-factor theory in developing and
maintaining phobias, Mowrer suggested that the anxiety characteristic of phobia is
acquired in two stages. Firstly, the fear becomes conditioned to the environment that
precedes the aversive situation. Secondly, the person then learns an "instrumental or
operant behavior that will successfully terminate the feared stimulus" (Klein, 2002, p.
167). Although Mowrer acknowledged the role of classical conditioning and its primacy
in the acquisition of phobic anxiety, he hypothesized that avoidance learning was critical
in the maintenance of anxiety (Klein, 2002; Mowrer, 1947). He suggested that a phobia
will "fail to extinguish if one successfully learns to avoid the feared stimulus" (Barlow,
2004, p. 236). The phobia causes an escape and/or avoidance of the feared thing or
situation and this negatively reinforces the person's behavior when faced with the same
event or situation in future. This inability to extinguish the tie between the feared
stimulus and the avoidance response results is what Mowrer called the "neurotic
paradox." Mowrer describes this as "the paradox of behavior which is at one and the
same time self-perpetuating and self-defeating" (Mowrer, 1950, p. 486). For Mowrer
people should optimally and rationally consider and weigh out the consequences
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associated with their behavior. In the event that the outcome of such a consideration is
favorable, the behavior should be continued; however, if the outcome is unfavorable, the
behavior should be stopped. Moreover, he argues that most people are aware that, in the
situations they avoid, there is nothing of which to be fearful in reality and that an accurate
appraisal of their options between a favorable and unfavorable behavior should lead to an
abandoning of avoidance behaviors. Despite the possibility for this cognitively mediated
weighing process, however, most phobic individuals fail to stop their self-defeating
behavior (Barlow, 2004; Mowrer, 1947; Mowrer 1950). Employing defense mechanisms
to alleviate the anxiety further facilitates the behavior of avoiding or escaping.
Defense Mechanisms. Relevant to a discussion of anxiety, it is important to
understand what happens when an individual experiences overwhelming amounts of
anxiety generally from a non-identifiable or internally cued source. Stemming from
Freud's perspective on anxiety, defense mechanisms are viewed as means of anxiety
reduction deployed, at an unconscious or automatic level, in any of the following
conditions: when the id impulses are in conflict either with one another or with the
superego, or when an external threat is posed to the ego (Freud, 1937). Anna Freud
greatly extended upon Freud's definition of defense mechanisms in the Ego and
Mechanisms of Defense, published in 1936. Defense mechanisms were conceptualized
either as intrapsychic mechanisms that distort the id impulses into an acceptable form or
that block id impulses from conscious awareness. The work of both Sigmund and Anna
Freud posited a variety of different defense mechanism, many of which have entered into
everyday language, such as denial. Some defense mechanisms are considered to be more
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adaptive or healthy than others. Freud considered sublimation to be the most productive
defense mechanism as opposed to the others he identified (Cramer, 2006; Freud, 1937).
Currently, the Diagnostic and Statistical Manual of Mental Disorders, 4th edition,
Text Revision (DSM-IV-TR) offers a more behaviorally explicit and less theoretically
bound definition of defense mechanisms as "automatic psychological processes that
protect the individual against anxiety and from awareness of internal or external dangers
or stressors" (American Psychiatric Association [APA], 2000). Examples of defense
mechanisms include regression (where an individual reverts back to an earlier stage of
development) or intellectualization (where an individual concentrates on the intellectual
components of a situation in order to distance him/herself from the emotions associated
with the situation). It is generally accepted that defense mechanisms are healthy and
helpful coping mechanisms, although there are instances where these mechanisms can
serve a maladaptive purpose. Such is the case when the employment of the defense
mechanism leads to a chronic avoidance of or delay in taking necessary action. For
example, denying the possibility of being exposed to HIV will lead a person to avoid
taking a HIV test.
Anxiety and related disorders. According to a study by Kessler et al. (1994),
anxiety and its related disorders are among the most common mental health concerns. In
fact, because of the variety of the ways in which anxiety can impact an individual, there
has been a continued trend toward a greater diagnostic specificity in the arena of anxiety
disorders. Within the Diagnostic and Statistical Manual, considerable changes have taken
place throughout the years, resulting in the growing length and specificity of each new
edition (Rogler. 1997). The number of anxiety related disorders, for example, has
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increased in every edition of the Diagnostic and Statistical Manual and each subsequent
edition has emphasized a greater behavioral specificity of the disorders grouped within
that category. Such is the case with specific phobia, defined by the DSM-IV TR (APA,
2000) as the excessive, unreasonable, and persistent anxiety triggered by an object or
situations.
Anxiety disorders are diagnosed by criteria set forth in the DSM-IV-TR. Seven
principle diagnoses have been identified: Panic Disorder, Agoraphobia, Specific Phobia,
Generalized Anxiety Disorder (GAD), Obsessive-Compulsive Disorder, Posttraumatic
Stress Disorder, and Acute Stress Disorder. All these disorders are predicated upon
clearly present feelings of anxiety (APA, 2000). The feelings of anxiety differ, however,
across the spectrum of anxiety disorders. Phobic anxiety differs from the experience of
anxiety in disorders such as Generalized Anxiety Disorder, Agoraphobia, and Panic
Disorder. For example, in the instance of a specific phobia, anxiety is manifested only in
the presence of the phobic object or situation; on the other hand, in GAD, anxiety is
almost always present in the form of worry and is in fact not focused on any specific
context or object. Until the fourth publication of the Diagnostic and Statistical Manual, in
1994, there was no meaningful classification within the area of specific phobias (Barlow
& Durand, 2001; Rogler, 1997). Currently, the areas of specific phobias are categorized
by the DSM-IV-TR as animal, natural environment, blood-injection, and situational type.
Each of these types consists of various stimuli that become the focus of the anxiety. For
example, in Blood-and-Injection phobia, the individual's experience of anxiety is cued by
seeing an injury or blood or by receiving an injection (APA, 2000). Following is a brief
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discussion on some of the specific stimuli that could trigger feelings of anxiety in
individuals as they may pertain to the topic of HIV testing.
Anxiety and HIV Testing
When applying the information with regards to anxiety to the specific case of HIV
testing, I argue that the possible fears associated with the situation can include, but are
not limited to, medical and death anxiety.
The fear of death is guided by several theories. Becker (1973) argues that all
living things share the drive to continue existing, and that the human brain is the most
successful survival mechanism. In addition, he also states that the fear of death is natural
and it is present in everyone. As soon as the individual is able to think, he or she will
realize the drive to continue existing as well as the fact that he or she will die. To Becker
this contradiction is at the root of our human anxiety (Liechty, 2000). Firestone (1993)
states that despite the fact of our mortality, individuals generally deny or displace their
fear of death in order to continue functioning everyday without being overwhelmed by
the anxiety caused by the knowledge or foreknowledge of their own demise. The various
defenses used to manage the anxiety of death are apparent in a study by Ford, Ewing,
Ford, Ferguson and Sherman (2004). Those college students who were primed for anxiety
associated with death by first completing death anxiety measure as opposed to
completing the death anxiety measure at the end of the session, were found to exhibit a
denial-based defensive activity which correlated with a significant increase in self reports
of a willingness to engage in high-risk sexual behavior. Safren, Gershuny, and
Hendriksen (2003) found that, when controlling for variables of depression and the
satisfaction with social support, death anxiety was still associated with overall Post-
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Traumatic Stress Disorder (PTSD) symptoms among patients with HIV. They argue that
receiving the diagnosis of HIV is a chronic stressor similar to the trauma experienced by
individuals who develop PTSD.
Medical anxiety is similar to the widely researched dental anxiety and refers to a
context-specific anxiety related to aversive affect and anxiety related avoidance in
various medical and healthcare situations. Prior research investigating the impact of
dental anxiety on behaviors such as routine checkups and more invasive dental
interventions has consistently shown a strong association between dental fear and delay
in or avoidance of treatment (Abrahamsson, Berggren, Hallberg & Carlsson 2002; Corah,
O'Shea, & Skeels, 1982; Kleinknecht & Bernstein, 1978). Limited research into the
connection of medical fear and healthcare behaviors suggests that patients who express
high levels of medical anxiety are more likely to delay receiving treatment for an acute
and life-threatening medical concern (e.g., angina) than are individuals with lower levels
of medical anxiety (Fowler, 1996). When considering the HIV testing process, various
potentially anxiety provoking stimuli can be identified such as that the individual to be
tested may be exposed to various medical procedures (e.g. blood being drawn), the
general healthcare situation (e.g. discussing results with a physician) as well as medical
concepts (e.g. germs and disease).
It is likely that anxiety related to HIV/ AIDS shares many commonalities with
specific phobias, in that at least some of the anxiety elicited by HIV/ AIDS is bound to a
specific stimuli or contexts, such as death and medical anxiety. For example, being
fearful of medical procedures, such as blood drawing required by a number of HIV tests,
or being fearful of contracting the actual disease both may serve as factors preventing
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individuals from getting their serological status checked in the first place or causing them
to fail to return. However, beyond specific phobias, HIV testing also likely elicits
broader based anxieties such as the anxiety surrounding death: a positive HIV test,
assuming its accuracy, is ultimately a death sentence and likely to evoke deep fears in the
individual being tested. Employing Mowrer's two-factor model, people's avoidance of
being tested and their failure to return for HIV test results can be seen as behaviors of
escape and avoidance, not just of the situation surrounding HIV testing, but also of the
feared stimulus, AIDS, as well. The behavior of individuals (particularly those engaged
in high-risk activities) who avoid testing becomes self-defeating, as an early diagnosis
and treatment of HIV could extend their lives and the moral anxieties about inadvertently
spreading the disease could be eliminated by an accurate knowledge of HIV status.
Despite compelling reasons to be tested, many individuals avoid being tested.
Despite the distinct possibility that anxiety plays a role in decisions concerning
HIV testing - for example, as a causal factor influencing failure to return for the results
of HIV testing - an extensive literature review yielded no study that specifically
examined the association between anxiety and HIV testing behavior. Moreover, even
finding studies that make mention of the possible role of anxiety in individual attitudes
toward facets of HIV testing are far and few between, with most of the focus to date
falling on samples drawn from outside the USA or consisting of individuals who have
already tested HIV positive. One such study by Buckingham (1987) addresses the unique
concerns of women and AIDS. The article suggests that those women who test positive
for HIV have a heightened anxiety, hence retreating into defense mechanisms, such as
denial, and becoming preoccupied with maintaining health.
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Anxiety experienced specifically within the HIV testing situation is briefly
mentioned in a study by Sullivan et al. (2004) in which self-reported failure to return
amongst high-risk persons revealed that, if during pretest counseling. There is an
increased focus on the individual's fear of learning their HIV status, this ultimately leads
to a significant reduction in the frequency of failure to return. Lyter at al. (1987)
examined the reasons gay and bisexual men decided whether or not to receive their HIV
test results. The researcher invited 2047 men who previously enrolled in the Pitt Men's
Study by mail asking them whether they would want to learn their HIV test results.
Additionally, they were asked to complete a questionnaire to assess, amongst other
variables, their reason for wanting to know or not know the results. Those who indicated
they wanted to know their status were seen by a clinician. Of the participants, 54%
learned their results, 7% indicated they wanted to receive their results but failed to meet
the clinician for a disclosure meeting, 9% formally declined to receive their results and
the remaining 30% of the participants failed to respond to the invitation. Of those gay or
bisexual men who declined to be informed of their status, 31% cited concern about the
harmful psychological impact a positive result might have on them. Forty-eight percent
of the respondents indicated that "a positive test result would be too worrisome, and 28%
believed that if their results were positive they would be "afraid to have sex" (Lyter et al.,
1987, p. 471). Worthington and Myers (2003) explores the social and situational factors
underlying anxiety during diagnostic testing. Information from interviews with 41 test
recipients was analyzed and four main themes related to anxiety were identified.
Throughout the interviews, participants identified themes of perception of risk and
responsibility, the social experience of HIV and stigma, the patient-provider power
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dynamic, and techniques used by test recipients to enhance a sense of control in the
interaction between self and the provider. The authors go on to discuss practical
implications for providers, such as explicitly addressing a patients anxiety over perceived
risk; reinforcing testing behavior, promoting further health changing behavior, and the
importance of test provider's demeanor' and behavior during testing.
More studies can be found that discuss anxiety and fear of HIV/AIDS in a more
general sense and not only limited to the testing situation. Attitudes and feelings related
to HIV/AIDS were studied by Kaijaleena and Aavarinne (1999) in a study in which 245
university students in Finland were assessed on their attitudes and feelings towards
HIV/AIDS. Respondents in this study expressed more negative and intensive feelings
towards AIDS than HIV, with fear about HIV being linked to the fear of contracting
AIDS. Additionally, students identified feelings of fear towards HIV/ AIDS such as
fearing AIDS because it leads to death and fearing contracting HIV as it was "unfair and
as a factor limiting people's sexual behavior" (Kaijaleena & Aavarinne, 1999, p. 466).
Waldner, Sikka, and Baig (1999) list several studies with regards to the fear of AIDS,
stating that in the past it has been established that the fear of AIDS is linked to the fear of
casual contact with another person who has AIDS rather than a fear of personally
contracting AIDS. Goodwin & Roscie (as cited in Waldner et al., 1999) found in a
sample of 109 university students in the Southwestern USA that the fear of AIDS is
higher amongst men than women. Furthermore, the study established that AIDS
knowledge varies across different ethnical groups, with African Americans having the
lowest scores. AIDS knowledge is important inasmuch as past research suggests a link
between AIDS knowledge and fear of AIDS. For example, Chliaoutakis and Trakas
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(1996) collected data from 1552 respondents in Attica, Greece and found that the higher
the level of AIDS knowledge, the lower the level of discrimination and stigmatization.
Furthermore, the researchers attempted to understand the relationship between AIDS and
fear by looking at underlying factors, and although they argue that risk perception may
play a part, this did not appear to make sense in all the cases. Due to the paucity of prior
research, I believe that an examination of the role of anxiety and defense mechanisms and
the ways in which anxiety is involved in avoidance behaviors can provide a deepened
understanding of the reasons underlying avoidance of HIV testing and the failure to
return for HIV test results.
Current Study
Recent numbers estimate that in the U.S.A. about 1 million people are living with
HIV or AIDS. Of these individuals, approximately 250,000 are unaware of their infection
(CDC, 2005). In an attempt to understand why there is such a vast amount of infected
people unaware of their HIV status, one can possibly explain this by looking at current
HIV testing behavior as it is reported in the USA's population. During the year 2002,
approximately half of all men and women between 15-44 years of age reported that they
had been tested at least once for HIV, which leaves the other half of the population as
never being tested (Anderson, Chandra, & Mosher, 2005). Furthermore, studies suggest
that typically about half of the individuals who do take a HIV test fail to return for the
results of their test (Dinh et al., 2005; Hightow et al., 2003; Strauss et al. 2002; Sullivan
et al., 2004). These statistics about HIV testing behavior indicate that an alarming number
of individuals are likely to remain ignorant of their HIV status, either due to not having
their HIV status tested at all or a failure to return to receive the results of FIIV testing.
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This research examined the role anxiety plays in individual decision-making concerning
HIV testing behavior. Due to the high probability that being tested for a life-threatening
disease provokes anxiety, it was hypothesized that anxiety influences the likelihood both
of submitting to an HIV test in the first place and of returning for the results of HIV
testing after one has decided to be tested.
The concept of anxiety is both broad and multifaceted; therefore, the research
examined the relationship of both broad-based anxiety and more domain-specific (or
narrow-band) types of anxiety and attitudes about HIV testing behavior. At its broadest
iteration, I assessed trait-based anxiety and the physical, cognitive, and affective
symptoms generally associated with anxiety disorders. The domain-specific types of
anxiety investigated were facets of medical-context anxiety (specifically those related to
germs, the hospital environment, medications, and Blood/Injection/Injury), Death
anxiety, and AIDS-Specific anxiety. The role of each of these types - or contexts - of
anxiety, individually or in combination, was examined vis-a-vis its impact on HIV testing
behavior.
Hypotheses. Prior research and speculations based on theory permit basic
hypotheses as to how the above mentioned independent variables would impact the two
dependent variables: the likelihood to being tested for HIV or the likelihood to return for
HIV tests results. Hypotheses for each of the dependent variables are presented below.
Hypotheses concerning the Likelihood of Being Tested for HIV Status:
1. Higher levels of General anxiety, as measured by both the state and trait-versions
of the STAI, will be associated with lower levels of the likelihood to acquire HIV
status.

2. Higher levels of endorsement of anxiety related symptoms, as measured by the
SAS, will be associated with lower levels of the likelihood to acquire HIV status.
3. Higher levels of AIDS-Specific anxiety, as measured by the MAAQ, will be
associated with lower levels of likelihood to acquire HIV status.
4. Higher levels of Blood/Injection/Injury anxiety, as measured by the B/I/I subscale
of the MAS, will be associated with lower levels of the likelihood to acquire HIV
status.
5. Higher levels of Germs anxiety, as measured by the Germs Subscale of the MAS,
will be associated with lower levels of the likelihood to acquire HIV status.
6. Higher levels of anxiety about taking medications or pharmacist error, as
measured by the Medications and Pharmacist subscale of the MAS, will be
associated with lower levels of likelihood to acquire HIV status.
7. Higher levels of anxiety about being in the hospital or having to undergo
treatment in a medical center, as measured by the Hospital and X-Ray Anxiety
subscale of the MAS, will be associated with lower levels of likelihood to acquire
HIV status.
8. Higher levels of Death anxiety, as measured by the DAS, will be associated with
lower levels of likelihood to acquire HIV status.
Hypotheses concerning the Likelihood of Returning for HIV Test Results.
1. Higher levels of General anxiety, as measured by both the state and trait-versions
of the STAI, will be associated with a higher likelihood of failure to return for
HIV test results.
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2. Higher levels of endorsement of anxiety related symptoms, as measured by the
SAS, will be associated with a higher likelihood of failure to return for HIV test
results.
3. Higher levels of AIDS-Specific anxiety, as measured by the MAAQ, will be
associated with a higher likelihood of failure to return for HIV test results.
4. Higher levels of Blood/Injection/Injury anxiety, as measured by the B/I/I subscale
of the MAS, will be associated with a higher likelihood of failure to return for
HIV test results.
5. Higher levels of Germs anxiety, as measured by the Germs Subscale of the MAS,
will be associated with a higher likelihood of failure to return for HIV test results.
6. Higher levels of anxiety about taking medications or pharmacist error, as
measured by the Medications and Pharmacist subscale of the MAS, will be
associated with a higher likelihood of failure to return for HIV test results.
7. Higher levels of anxiety about being in the hospital or having to undergo
treatment in a medical center, as measured by the Hospital and X-Ray anxiety
subscale of the MAS, will be associated with a higher likelihood of failure to
return for HIV test results.
8. Higher levels of Death anxiety, as measured by the DAS, will be associated with a
higher likelihood of failure to return for HIV test results.
Study Design. The design of the study was passive observational/correlational. The
study examined how a group of independent variables (namely, various types of anxiety)
impact two separate dependent variables: likelihood of acquiring HIV status (via being
tested) and likelihood of returning for results of the HIV status testing. Furthermore, this
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study controlled for certain extraneous variables that have been identified as potentially
impacting HIV testing behavior.
The dependent variables for this study were identified as the Likelihood of Being
Tested for HIV and the Likelihood of Returning for HIV Test Results. The independent
variables for this study were identified as General anxiety, AIDS-Specific anxiety,
Blood/Injection/Injury anxiety, Germs anxiety, Hospital and X-Ray anxiety, Medications
anxiety, and Death anxiety. The extraneous variables identified for this study were
gender, ethnicity, relationship status, previous HIV testing behavior, past sexual history,
HIV related knowledge, current HIV risk and personal experience of HIV/ AIDS.

Method
Participants
Participants were 347 students in introductory or advanced-level psychology
classes attending Western Kentucky University. Of the original sample of participants,
five participants were removed from the sample due to excessive missing data. These
participants failed to answer the questions adequately, leaving their questionnaire with
more than 25% missing data. The final sample retained 342 participants. Participants
were recruited in psychology classes and received either the research credit required for
the class or extra credit for their participation in the study. There were 129 (37.7%) male
participants and 208 female (60.8%) participants. Regarding ethnicity, there were 293
(85.7%) Caucasian participants, 24 (7%) African-American participants, 12 (3.5%) Asian
participants, 8 (2.3%) Bi-Racial or Multiracial participants, 2 (.6%) Hispanic or Latino
participants, 2 (.6%) Native American or Alaska Native participants and 1 (.3%) Native
Hawaiian/ Pacific Islander participant. Regarding the participant's educational level,
there were 186 (54.45) participants who classified themselves as first-year college
students, 69 (20.2%) who endorsed themselves as second-year college students, 48 (14%)
as third-year college students, and 38 (11.1%) who endorsed themselves as fourth-year
college students. With regards to the participant's relationship status, 134 (39.2%)
participants reported being single, 161 (47.1%) participants reported being in a
relationship, 12 (3.5%) were living with their partners, 18 (5.3%) were engaged, and 16
(4.7%) reported being married. When queried about prior sexual activity, 251 (73.4%)
reported that they have been sexually active, and 87 (25.4%) reported that they had never
been sexually active. Regarding a history of HIV testing, 60 (17.5%) participants
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reported that they had previously taken a HIV test, and 282 (82.5%) reported no prior
HIV testing. Five participants (1.5%) did not indicate their gender, 1 (.3%) participant
failed to indicate his/her current school year, 1 (.3%) participant did not indicate
relationship status, and 4 (1.2%) participants failed to respond to the item concerning past
sexual history.
Measures
Vignettes. For the purpose of this study, the researchers created a vignette about
HIV testing. The vignette asked participants to imagine that they are able to receive a
HIV test today that will be free of charge, anonymous, and tailored to their expectations
(i.e. they can pick the specimen, test type, result time frame, etc.). The participants were
asked to rate the likelihood that they would take the HIV test if the prescribed parameters
obtained as well as rating the likelihood that they will return to receive the HIV test
results (See Appendix A). Participants were asked to rate the likelihood of engaging in
these HIV testing-related behaviors on a ten-point Likert-type scale on which a rating of
"1" would indicate that they are "not likely at all," a rating of "5" would indicate that
they are "somewhat likely," and a rating of "10" would indicate that they are "extremely
likely" to act in the described manner. Responses on these two scales were used as the
dependent variables during the stepwise multiple regressions.
Demographics. Participants were asked to provide information regarding
demographics (such as age, ethnicity, etc.), relationship history, and HIV/AIDS related
information. Research suggests that certain factors are associated with an increased
likelihood of failing to return for HIV test results. For example, Hightow et al. (2003)
found that failure to return was more common among African Americans and individuals
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with a prior history of failure to return. Considering the potential role of demographic
variables, participants were asked to answer questions concerning their gender, age,
ethnicity, and current school year, as well as the highest educational level achieved by
their mother and father (See Appendix B). Furthermore, each participant was asked to
answer questions pertaining to personal relationship history, including information
concerning marital status, sexual orientation, and whether he or she has a history of being
sexually active (See Appendix C). Additionally, participants answered questions relating
to HIV/ AIDS and HIV testing (See Appendix D). Specifically, each participant was
asked whether she or he personally knows or has known someone with HIV/AIDS. Prior
research has suggested that such HIV-related factors as knowing someone with
HIV/AIDS influences the HIV-related attitudes as well as the likelihood of having HIV
status tested (Macintyre, Brown & Sosler, 2001; Camlin & Chimbwete, 2003).
Additionally, since past experience with HIV testing as well as the objective
characteristics of the testing context have been associated with the failure to return for
HIV testing (Keenan & Keenan, 2001; Sullivan et al., 2004) each participant was also
asked questions concerning his or her past HIV testing behavior, such as whether he or
she had ever taken an HIV test and whether or not he or she knew his or her own HIV
status. The participant's responses to these questions were used for descriptive statistics
as well as to control for extraneous variables.
State-Trait Anxiety Inventory. The State-Trait Anxiety Inventory (STAI;
Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983) consists of two 20-item selfreport measures that assess state and trait levels of anxiety. Standardized administration
involves administering the state version prior to the trait version. Respondents indicate
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how much each statement reflects how they feel right now, at this moment (state version),
or how they generally feel (trait version) on four-point Likert-type scales. Participants are
expected to rate these statements by indicating either a 1 if the statement is 'not at all'
like them, a 2 if it is 'somewhat' like them, a 3 if it is like them 'moderately so,' and a 4
if the statement is 'very much so' like them. Sample items from the state version include
"I feel frightened" and "I feel pleasant." Sample items from the trait version include "I
wish I could be as happy as others seem to be," "I am a steady person," and "I have
disturbing thoughts." Both scales can be administered in 10 minutes. Anxiety-absent
items on each scale are reverse-scored, and the 20 items of each scale are then summed
for total scores. Scores can range from 20 to 80, with a higher score indicating higher
levels of anxiety. The STAI shows good to excellent internal consistency for both scales
(alphas between .86 and .95) in adult, college, high school student, and military recruit
samples. Convergent validity for the trait-version of the STAI has been demonstrated in
significant correlations with other trait measures of anxiety for both Form Y and Form X
(the prior STAI form) in normal populations (e.g., Creamer, Foran, & Bell, 1995;
Spielberger et al., 1983). The total scores on each scale of this measure were used as
independent variables in the study, indicating the participant's general level of anxiety.
Self-Rating Anxiety Scale. The Self-Rating Anxiety Scale (SAS; Zung, 1971;
Appendix E) is a rating instrument developed for the measurement of the most commonly
agreed upon symptoms of anxiety. The instrument primarily measures somatic symptoms
associated with anxiety (Olatunji, Deacon, Abramowitz, & Tolin, 2006). The SAS is the
self-report component of a two-part instrument: the first part of the instrument, the
Anxiety Status Inventory (ASI) is designed as an instrument to facilitate interview rating
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of the examinee, whereas the SAS is a self-report instrument. The SAS consists of 20
items using a four-point Likert-type scale on which each participant is expected to rate
how much each of the items have applied to him/ herself within the last week. The
participant responds with a "1" if the item has applied to him/ herself "none or a little of
the time," "2" if it applied "some of the time," a "3" if it applied a "good part of the
time," and a "4" if the item has applied to him/ herself "most or all of the time." Sample
items from the SAS include "I feel more anxious and nervous than usual" and "I can
breathe in and out easily." A total score is obtained by reverse scoring the items stated in
an anxiety absent manner and then summing the 20 items of the SAS (Zung, 1971).
Scores can range from 20 to 80, with a higher score indicating higher l evels of anxiety.
The psychometric properties of the SAS appear to be solid. Zung (1971) reported an oddeven split-half reliability of .71 and an internal consistency of .85. Additionally Jegede
(1977) reported that the measure has demonstrated adequate internal consistency and testretest reliability. In correlational analysis between the SAS and other measures of
anxiety, evidence of convergent validity was found, although evidence for discriminant
validity is limited (Olatunji et al., 2006). The total score from this measure was used as
an independent variable in the study, indicating the participant's general level of anxiety.
Medical Anxiety Scale. The Medical Anxiety Scale (MAS; Pegg & Gardner,
2006) is a measurement currently in development. That aims at being a comprehensive
measure of the full spectrum of medical anxieties. The MAS includes facets already
assessed by measures such as the Medical Fear Survey and Medical Avoidance Survey
(Kleinknecht, Thorndike, & Walls, 1996), and the General Medical Anxiety Index (Van
Balen & Verdurmen, 1999). Furthermore, the MAS includes items assessing for both

40

anxiety related to delay in seeking medical care and medical attention, as well as anxiety
related avoidance of medical care and treatment. For the present study, the following
specific subscales were culled from the MAS to assess anxiety in contexts potentially
related to HIV testing or the treatment of AIDS: Blood/Injection/Injury Anxiety (See
Appendix F); Germs Anxiety (See Appendix G); Hospital and X-Ray Anxiety (See
Appendix H); and, Medications and Pharmacist-Related Anxiety (See Appendix I).
Internal consistencies of the subscales employed in the present study, assessed during the
development of the measure, vary between .85 (for the Germs Anxiety and Hospital and
X-Ray anxiety subscales) and .92 (for the Blood/Injection/Injury subscale). The
participant is presented with various statements relating to attitudes toward healthcare
personnel and medical situations. The participant is expected to use the six-point Likert
type scale to indicate the extent to which he or she agrees or disagrees with each
statement. The six points of the scale are as follows: "1" is "Strongly Disagree"; "2" is
"Somewhat Disagree"; "3" indicates "Slight Disagreement" with the statement; "4" is
"Slightly Agree"; "5" is "Somewhat Agree"; or, "6" is "Strongly Agree". A total score is
obtained by first reverse scoring those items that are stated in an anxiety absent manner,
and then summing all the items of each subscale. The total scores from these subscales
were used as independent variables in the study, indicating the participant's levels of
Blood/Injection/Injury, Germs, Hospital and X-Ray, and Medications and Pharmacist
Anxiety.
Death Anxiety Scale. The Death Anxiety Scale (DAS; Templer, 1970; Appendix
J) is one of the few measures of death anxiety. The DAS consists of 15 true-or-false
statements (e.g. "I am very much afraid to die," "The thought of death seldom enters my
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mind," and "It doesn't make me nervous when people talk about death"). A recently
extended version includes the original 15 items as well as an additional 36 new items
(Templer et al., 2006). Although the internal consistency for the extended scale is
superior to the original version of the measure, Templer et al. (2006) states that
researchers should consider both the participant's time and the purposes for which the
measure is being used when deciding which version of the scale to adopt. The scale is
scored by summing the anxious positive responses. Scores can range from 15 to 30, with
a higher score indicating higher levels of death anxiety. Among the advantages of using
the DAS as a measure of death anxiety are its brevity and ease of scoring, as well as its
prior use in hundreds of studies (Templer et al., 2006). The instrument has also been
formatted into a Likert format and has been used as such in other studies (Safren,
Gershuny & Hendriksen, 2003; McMordie, 1979). Additionally, the scale has been
translated into various different languages including Afrikaans, Arabic, Chinese, Dutch,
French, German, Hindi, Italian, Japanese, Korean, Portuguese, Russian, Spanish, and
Swedish (Templer et al., 2006). Stevens, Cooper and Thomas (1980) established age
norms for the true-false format of the DAS. Psychometric properties for the DAS were
found to be good with a test-retest reliability of .83 and a Kuder-Richardson internal
consistency coefficient of .76 (Templer, 1970). In addition, Handal (1975) validated the
DAS as an acceptable measure of the defense mechanism of repression. The total score
from this measure was used as an independent variable in the study, indicating the
participant's level of Death anxiety.
Multidimensional AIDS Anxiety Questionnaire. An exhaustive review of the
literature yielded only one measurement for the assessment of AIDS-specific anxiety.
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Snell and Finney (1996) developed the Multidimensional AIDS Anxiety Questionnaire
(MAAQ; 1996; Appendix K) consisting of 50 Likert-type scale questions assessing
several areas of anxiety related to AIDS. These areas are: physiological arousal (as
reflected by the item: "When I think about AIDS, I feel tense"), fear of AIDS (as
reflected by the item: "I'm afraid of getting AIDS"), sexual inhibition (as reflected by the
item: "AIDS makes me feel jittery about having sex with someone."), cognitive worry (as
reflected by the item: "thinking about AIDS makes me feel anxious."), discussion
inhibition (as reflected by the item: "I sometimes find it hard to discuss issues dealing
with AIDS.") and anxiety about AIDS (as reflected by the item: "I'm concerned that I
might be carrying the AIDS virus."). Each participant is expected to rate his or her
response to these statements on a five-point Likert-type scale. Participants indicate a 1 if
the response is 'Not at all characteristic of me;' a 2 for 'Slightly characteristic of me;' a 3
for 'Somewhat characteristic of me;' a 4 for 'Moderately characteristic of me;' and a 5 if
the statement is 'Very characteristic of me.' The MAAQ is scored by reverse scoring the
items that are anxiety absent after which the participant's responses are summed to yield
a total score. The MAAQ shows high internal consistency (alphas of these various areas
ranging between .85 and .94) (Snell & Finney, 1996). Scores can range from 50 to 250,
with a higher score indicating higher levels of AIDS-specific anxiety. The total score
from this measure was used as an independent variable in the study, indicating the
participant's level of AIDS-specific anxiety.
HIV Risk Assessment. In order to obtain a level of each participant's current HIV
risk exposure, questions adopted from the CDC's published guidelines for HIV
counseling, testing, and referral (CDC, 2001, Appendix L) were used. Participants can
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complete this screening instrument either during a face-to-face interview, through a
computer assisted interview, or by self report; however insufficient data exist to support
the efficacy of any one of these approaches over any of the others (CDC, 2001). The
assessment includes 6 true-false statements that assesses the individual's potential
exposure to HIV due to behavioral risk (e.g. "Since your last HIV test [if ever], have you
injected drugs and shared equipment [e.g., needles, syringe, cotton water] with others?")
as well as assessing some clinical signs (e.g. Since your last HIV test [if ever], have you
had a fever or illness of unknown cause?"). If a participant responds true to 1 or more of
these 6 statements, he/she should be considered at an increased risk for HIV exposure.
For the purpose of this study, each participant's responses will be summed to yield a total
score indicating the participant's overall HIV risk. Scores can range from 0 to 6, with a
higher score indicating higher levels of HIV risk. The total score from this measure was
used in the study to control for the impact of current HIV risk on the dependent variables.
HIV Knowledge Questionnaire. As noted above, several studies have indicated
that knowledge about HIV/AIDS appears to be a determinant of behavior change (Carey
& Schroder, 2002; Chliaoutakis & Trakas, 1996; Waldner et al., 1999). Participant's level
of HIV/AIDS knowledge was assessed by completing the HIV Knowledge
Questionnaire, 18 item version (HIV-KQ-18; Carey & Schroder, 2002; Appendix M).
The HIV-KQ-18, is a shortened version of the original HIV Knowledge Questionnaire
(HIV-K-Q), which consisted of 45 items (Carey, Morrison-Beedy, & Johnson, 1997). The
HIV-KQ-18 consists of items aimed at measuring an individual's self-reported HIVrelated knowledge. The participant is required to respond to fact-based questions about
HIV by indicating whether the presented statement is 'True' or 'False.' The measure is
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scored by summing the number of correct responses. Scores can range from 0 to 18, with
a higher score indicating better knowledge of HIV/AIDS. The HIV-KQ-18 demonstrated
good internal consistency (alphas ranging between .79 and .89) as well as good test-retest
reliability (ranging between .76 and .94) and correlational analysis indicated strong
associations with other measures such as the HIV-K-Q (Carey & Schroder, 2002). The
total score from this measure was used in the study to control for the impact of HIV
knowledge on the dependent variables.
Procedure
Approval for this study was obtained from the Western Kentucky University's
Human Subjects Review Board (Appendix N). Upon approval, a research assistant
solicited participants in their various classes. Participants first signed an Informed
Consent form (Appendix O). All participants were then assessed on a general level of
anxiety by utilizing the STAI and the SAS. Participants were then required to complete a
section querying personal demographics, HIV-related demographics, and relationship
history. Additionally, participants completed the HIV-KQ-18 and an assessment of their
current HIV risk. Participants then completed the measures that assessed specific or
"narrowband" areas of anxiety: the MAAQ; the subscales of the MAS; and, the DAS.
To address concerns about position effect in the administration of the
assessments, two versions of the questionnaire packets used in the research were
developed. The measures of specific anxiety were randomly assigned to one of two test
versions. Each participant was then randomly assigned to either of the two test versions.
This allowed the researchers to counterbalance partially the data collected.
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Participants were required to complete the questionnaires online on a restrictedto-user university study board. The participants were required to have a password to login
to the University study board. The password was specific to a given participant and
provided by the study board administrator. Moreover, after logging into the study board
site, the participant must then opt to take the study and will not be able to access the
study without specifically signing up for it through the study board. No access to the
instruments being used in the study was permitted prior to the participant's consenting to
participate in the study, nor were the instruments available to the participants after
completion of the questionnaire.
After the participants completed the bulk of the questionnaires comprising the
research packet, a modified form of the state-version of the STAI was administered to
determine if taking the survey itself caused any transient changes in level of anxiety. The
instructions for the modified state-based anxiety inventory was framed so as to gauge the
sensations of anxiety or anxiety related affect experienced by the participants during the
administration of the research packet. At the conclusion of the research, a debriefing form
(Appendix P) was presented that provided the participants with a list of resources
available to them should they want to determine their HIV status. Contact information for
mental health services was also provided for the unlikely contingency that any participant
experienced distress as a consequence of his or her participation in the research. A list of
websites that present information about HIV/AIDS, such as the Center for Disease
Control's AIDS Awareness website, was also provided; notably, the CDC's website also
provides a list of free and anonymous HIV testing sites. The entire procedure took 60-90
minutes.

Results
Counterbalancing. The possibility of position effect was statistically managed via
counterbalancing. T-tests were conducted to determine if any significant difference was
obtained between the two different test versions. Independent samples t-tests were run
between the participant's responses on the STAI, SAS, MAAQ, MAS subscales, and the
DAS. The results of all of the performed t-test were non-significant suggesting no support
for a hypothetical position effect.
Missing Data. Missing data was replaced by performing an item-level mean
imputation of the missing variables. This procedure was used only to address missing
data on the measures of anxiety, i.e. on the STAI, SAS, MAAQ, MAS subscales, and the
DAS. On the State version of the STAI, 18 (5.3%) participants failed to answer at least 1
but no more than 3 items, resulting in missing data that was replaced through imputation.
On the Trait version of the STAI, 28 (8.2%) of the participants failed to answer at least 1
but no more than 3 items. On the SAS, 12 (3.5%) of the participants neglected to answer
the measure completely with the resultant use of mean imputation. On the MAAQ, itemlevel mean imputation was needed for 47 (13.7%) of the participants, who missed at least
1 but no more than 4 of the items. The frequency of this procedure on the different
subscales of medical anxiety were as follows: 10 participants (2.9%) on the
Blood/Injection/Injury subscale of the MAS; 11 participants (3.2%) on the Hospital and
X-Ray subscale of the MAS; 4 participants (1.2%) on the Germs subscale of the MAS;
and 7 participants (2%) on the Medications and Pharmacist subscale of the MAS missed
items and required mean imputation. On the DAS, item-level mean imputation was
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needed for 8 (2.3%) of the participants who missed at least 1 but no more than 2 of the
items.
After imputing the means of the items, item scores for each measure were then
summed, according to the requirements of each measure, to yield the relevant subscale
and total scores used in further data analysis.
Internal Consistency of Measures. In order to assess the reliability of the
measures used in the study, the internal consistency of each of the measures used as
independent variables during the multiple regression analyses was obtained. The
reliability of the measures for General (or broad-based) anxiety were as follows: State
anxiety (Cronbach's Alpha = .93), Trait anxiety (Cronbach's Alpha = .93), SAS
(Cronbach's Alpha = .83). Reliability scores for the measures of specific anxiety were as
follows: MAAQ (Cronbach's Alpha = .96) and DAS (Cronbach's Alpha = .79). The
reliability scores for the different measures of subtypes of medical anxiety were as
follows: the Blood/Injection/Injury subscale of the Medical Anxieties Scale (MAS)
(Cronbach's Alpha = .83), the Hospital and X-Ray subscale of the MAS (Cronbach's
Alpha =.86), the Germs subscale of the MAS (Cronbach's Alpha =.89), and the
Medications and Pharmacist subscale of the MAS (Cronbach's Alpha =.85).
Descriptive Statistics. The mean and standard deviation of the participants' total
scores on each of the measures of anxiety are provided in Table 4, as well as the range on
each of these instruments. Additionally, the participants are grouped according to their
responses on the demographic questions. The mean and standard deviation on each of the
measures of anxiety are provided according to the participant's gender (Male or Female)
in Table 5, ethnicity (Caucasian or Non-Caucasian) in Table 6, prior HIV testing history
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in Table 7, past sexual history in Table 8, and relationship status (Single or "In a
relationship") in Table 9.
Table 4
Descriptive Statistics of Participants' raw scores across the measures of anxiety.
Measure of Anxiety

Mean

Standard

Instrument

Deviation

Range

State Anxiety

38.15

11.15

20-80

Trait Anxiety

39.44

11.25

20-80

Self-rating Anxiety Scale

33.73

7.81

20-80

93.34

31.65

50 - 250

Blood/Injection/Injury

20.88

9.66

7-42

Germs

25.42

10.26

10-60

Hospital and X-Ray

35.37

12.31

11-66

9.27

10-60

3.53

15-30

Multidimensional AIDS Anxiety
Questionnaire
Medical Anxiety

Medications and Pharmacist 19.98
Death Anxiety

22.64
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Table

11

Descriptive Statistics of Male and Female raw scores across the measures of anxiety.
Male
Mean

Measure of Anxiety

Female
Standard

Mean

Deviation

Standard

Deviation

State Anxiety

37.57

11.28

38.41

11.02

Trait Anxiety

38.47

11.57

39.93

10.99

Self-rating Anxiety Scale

32.17

7.77

34.64

7.65

89.86

30.49

95.70

32.81

Blood/Injection/Injury

18.69

8.92

22.26

9.81

Germs

22.14

9.45

27.38

10.21

Hospital and X-Ray

33.05

11.03

36.63

12.85

8.40

20.47

9.69

3.30

21.97

3.52

Multidimensional AIDS Anxiety
Questionnaire
Medical Anxiety

Medications and Pharmacist 19.09
Death Anxiety

23.72
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Table

11

Descriptive Statistics of Caucasian and Non-Caucasian raw scores across the measures
of anxiety.
Caucasian
Mean
Measure of Anxiety

Standard

Non-Caucasian
Mean

Standard
Deviation

Deviation

State Anxiety

37.96

11.09

38.67

11.02

Trait Anxiety

39.13

11.04

41.04

12.21

Self-rating Anxiety Scale

33.65

7.88

33.99

6.89

91.33

30.78

106.92

35.53

Blood/Injection/Injury

20.52

9.62

22.73

9.39

Germs

25.24

10.19

26.36

10.40

Hospital and X-Ray

35.10

12.05

36.05

13.36

9.17

21.82

9.43

3.53

22.37

3.69

Multidimensional AIDS Anxiety
Questionnaire
Medical Anxiety

Medications and Pharmacist 19.62
Death Anxiety

22.65
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Table 11
Descriptive Statistics of Participant's (with history ofprior or no prior HIV testing) raw
scores across the measures of anxiety.
Prior HIV Test
Mean

Standard

No Prior HIV Test
Mean

Deviation

Deviation

Measure of Anxiety

Standard

State Anxiety

37.56

11.70

38.17

10.94

Trait Anxiety

39.21

12.00

39.21

11.06

Self-rating Anxiety Scale

35.85

8.81

33.24

7.43

92.94

31.05

93.70

32.15

Blood/Injection/Injury

20.19

10.25

20.97

9.47

Germs

26.31

10.92

25.20

10.06

Hospital and X-Ray

34.24

13.37

35.45

11.99

9.54

19.90

9.17

3.56

22.56

3.56

Multidimensional AIDS Anxiety
Questionnaire
Medical Anxiety

Medications and Pharmacist 20.11
Death Anxiety

22.83
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Table

11

Descriptive Statistics of Participant's (with histoiy of sexually active or no sexually
active historyj raw scores across the measures of anxiety.
Sexually Active Past
Mean

Standard

No Sexually Active Past
Mean

Deviation

Deviation

Measure of Anxiety

Standard

State Anxiety

38.42

11.04

37.20

11.17

Trait Anxiety

39.96

11.14

38.04

11.40

Self-rating Anxiety Scale

34.30

8.06

32.08

6.60

94.60

32.84

91.19

29.30

Blood/Injection/Injury

20.52

9.73

21.71

9.33

Germs

25.36

10.40

25.57

9.76

Hospital and X-Ray

35.25

12.23

35.40

12.43

9.30

20.12

9.13

3.51

23.18

3.56

Multidimensional AIDS Anxiety
Questionnaire
Medical Anxiety

Medications and Pharmacist 19.90
Death Anxiety

22.38
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Table

11

Descriptive Statistics of Single Participant's or Participants in a relationship's

raw

scores across the measures of anxiety.
Single
Mean
Measure of Anxiety

In a Relationship
Standard

Mean

Deviation

Standard
Deviation

State Anxiety

40.14

10.55

36.73

11.23

Trait Anxiety

41.34

11.68

38.15

10.77

Self-rating Anxiety Scale

34.00

7.73

33.51

7.78

99.18

32.83

89.45

30.09

Blood/Injection/Injury

20.69

9.74

20.93

9.56

Germs

24.36

10.34

26.11

10.09

Hospital and X-Ray

35.05

12.15

35.45

12.28

8.61

19.88

9.64

3.53

22.60

3.58

Multidimensional AIDS Anxiety
Questionnaire
Medical Anxiety

Medications and Pharmacist 20.04
Death Anxiety

22.64
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Furthermore, Table 10 presents the mean and standard deviation of each
participant's response to the likelihood of being tested for HIV and the likelihood of
returning for the results of HIV testing. Additionally, the mean and standard deviation of
participant's responses to the likelihood of being tested for HIV and the likelihood of
returning for the results of HIV testing are provided according to the participant's gender
(Male or Female), ethnicity (Caucasian or Non-Caucasian), prior HIV testing history,
past sexual history, and relationship status (Single or "In a relationship") in Table 11.
Table 10
Descriptive Statistics of Participants across the likelihood of being tested for HIV and the
likelihood of returning for the results of HIV testing.
Mean

Standard

Range

Deviation
Likelihood of Being
Tested for HIV Status

5.63

3.39

1 - 10

6.58

3.58

1 - 10

Likelihood of Returning for
the Results of HIV testing
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Table 11
Descriptive Statistics of Respondents across the likelihood of being tested for HIV and
the likelihood of returning for the results of HIV testing grouped by demographics
Likelihood of Being

Likelihood of Returning

Tested for HIV

for results of HIV test

Mean

Standard

Mean

Deviation

Deviation

Demograpics

Standard

Gender
Male

5.19

3.49

6.37

3.57

Female

5.90

3.32

6.66

3.51

Caucasian

5.49

3.41

6.41

3.54

Non-Caucasian

6.53

3.25

7.40

3.37

Prior HIV Testing

7.90

2.94

7.90

3.03

No Prior HIV Testing

5.14

3.29

6.25

3.57

Sexually Active Past

6.13

3.26

6.81

3.42

No Sexually Active Past

4.26

3.42

5.81

3.75

Single

5.30

3.46

6.35

3.53

In a Relationship

5.74

3.43

6.72

3.58

Ethnicity

HIV testing history

Sexual History

Relationship Status
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Likelihood of Being Tested for HIV. Hypotheses designed to answer research
questions related to the Likelihood of Being Tested for HIV were tested using a stepwise
regression analyses to determine which of the independent variables included in the data
analysis were the strongest predictor(s) of the likelihood of being tested for HIV.
Independent variables included State Anxiety (Total score from the State version of the
STAI), Trait Anxiety (Total score from the Trait version of the STAI), General Anxiety
(Total score from the SAS), AIDS-Specific Anxiety (Total score from the MAAQ),
Blood/Injection/Injury Anxiety (Total score from the MAS, Blood/Injection/Injury
subscale), Germs Anxiety (Total score from the MAS, Germs subscale), Hospital and XRay Anxiety (Total score from the MAS, hospital and X-Ray subscale), Medications and
Pharmacist Anxiety (Total score from the MAS, Medications and Pharmacist subscale),
and Death anxiety (Total score from the DAS). Stepwise regression revealed that a single
variable, AIDS-Specific Anxiety, was the strongest predictor of the likelihood of being
tested for HIV {R = .139, R2adj = .016, F( 1, 340) = 6.68, p = <.05). Overall, the model
retained after regression analysis accounted for only 13% of variance in the likelihood of
getting tested for HIV. See Table 12 for a summary of the overall model. Table 13
displays the bivariate and partial correlation coefficients for the final model.
Table 12
Model Summary for Variable(s) Predicting Likelihood of Being Tested for HIV

Step

AIDS-Specific Anxiety

R

R2

R2adj

.139

.019

.016

A R2

.019

Fchg

p

6.68

<.05

dfi

df2

1

340
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Table 11
Coefficients for Final Model Predicting Likelihood of Being Tested for HIV
B

AIDS-Specific Anxiety

.015

P

.006

t

2.58*

Bivariate r

.010

Partial r

.004

Note. *p < .05.
Likelihood of Returning for HIV Test Results. Hypotheses developed to answer
research questions related to the Likelihood of Returning for HIV Test Results were
tested using a stepwise regression analysis to determine which of the independent
variables were the strongest predictor(s) of the Likelihood of Returning for HIV Test
Results. The independent variables included in the analysis were State anxiety (Total
score from the State version of the STAI), Trait anxiety (Total score from the Trait
version of the STAI), General anxiety (Total score from the SAS), AIDS-Specific anxiety
(Total score from the MAAQ), Blood/Injection/Injury anxiety (Total score from the
MAS, Blood/Injection/Injury subscale), Germs anxiety (Total score from the MAS,
Germs subscale), Hospital and X-Ray anxiety (Total score from the MAS, hospital and
X-Ray subscale), Medications and Pharmacist anxiety (Total score from the MAS,
Medications and Pharmacist subscale), and Death anxiety (Total score from the DAS).
Stepwise regression revealed that a single variable, Hospital and X-Ray anxiety, was the
•y

strongest predictor of the Likelihood of Returning for HIV test Results (R = .121, R aeij =
.012, F(l, 340) = 5.07,p = <.05). Overall, the variable retained after regression analysis
accounted for only 12% of the variance of the model. See Table 14 for a summary of the
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overall model. Table 15 displays the bivariate and partial correlation coefficients for the
final model.
Table 14
Model Summary for Variable(s)Predicting Likelihood of Returning for HIV Test Results

Step

R

R2

R2adj

.121

.015

.012

AR2

F chg

p

df,

df2

1

340

Hospital and X-Ray
Anxiety

.015

5.07

<05

Table 15
Coefficients for Final Model Predicting Likelihood of Returning for HIV Test Results

B

P

t

Bivariate r

Partial r

Hospital and X-Ray
Anxiety

.035

.016

2.25*

.025

.004

Note. *p < .05.
Exploratory Analyses. Upon completion of the proposed study, several factors
influenced the decision to do exploratory analyses. When considering that the expected
results where not obtained and that unequivocal support for the proposed hypotheses was
not provided, I deemed it necessary to re-review the data collected in an attempt to
explore possible explanations as to the results. Considering the low amount of variance
attributed to the various anxiety measures, I decided to explore the impact of other
factors, specifically, the influence of the individual's demographics on the models. In
order to control for the effects of subject related extraneous variables on the
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aforementioned models, linear regression analyses were performed to determine to what
extent the extraneous variables influenced the likelihood of being tested for HIV as well
as the likelihood of returning for HIV test results. The participants responses to gender
(Male or Female), ethnicity (Caucasian or Non-Caucasian), previous HIV testing history
("Have taken a HIV test" or "Not taken a HIV test"), past sexual history ("Have been
sexually active" or "Have never been sexually active"), and relationship status ("Single"
or "In a relationship"), current HIV risk (Total score from the HIV risk assessment), and
HIV knowledge (Total score from HIV-KQ-18), were regressed onto each of the two
dependent variables and unstandardized residual scores were calculated. The
unstandardized residual score represents the variance in the dependent variable's score
after the variance that can be explained by the extraneous variables have been removed.
For this study i.e. it would mean that the unstandardized residual score for the likelihood
of being tested for HIV as well as the likelihood to return for the results represent the
likelihood that has been adjusted for the effect of the various demographics. The stepwise
regression analyses to determine which of the independent variables were the strongest
predictor(s) of the two dependent variables - that is, the likelihood of being tested for
HIV and the likelihood of returning for HIV test results - were repeated using the
unstandardized residual scores of each of these dependent variables. The stepwise
regression analysis revealed that no model was retained for either of the dependent
variables, i.e. none of the independent anxiety measures accounted for a significant
amount of variance in the models.
Furthermore, considering that there is such a scarcity in the literature with regards to
the influence of anxiety on HIV testing behavior as well as HIV/AIDS anxiety in general,

60

I decided to explore this area even thought this is not what I originally set forth to
accomplish. Considering the data collected I deemed that the most fruitful exploratory
analyses would be to explore, albeit briefly, the impact of the various factors on AIDSSpecific anxiety. This was accomplished by performing a stepwise regression analysis to
explore the influence of the various anxieties on AIDS-Specific anxiety. The independent
variables included: State anxiety (Total score from the State version of the STAI), Trait
anxiety (Total score from the Trait version of the STAI), General anxiety (Total score
from the SAS), Blood/Injection/Injury anxiety (Total score from the MAS,
Blood/Injection/Injury subscale), Germs anxiety (Total score from the MAS, Germs
subscale), Hospital and X-Ray anxiety (Total score from the MAS, hospital and X-Ray
subscale), Medications and Pharmacist anxiety (Total score from the MAS, Medications
and Pharmacist subscale), and Death anxiety (Total score from the DAS). The dependent
variable was the participants reported AIDS-Specific anxiety (as indicated by the total
score from the MAAQ). Results revealed an overall model of three predictors: Death
anxiety (R = .57, R2adj = .255, F{ 1, 340) = 117.85,p = <.05); Germs anxiety (R = .56,
R2adj = -315, F( 1, 339) = 30.82,p = <.05) and Trait anxiety (R = .57, R2adj = .327, F( 1,
338) = 26.18,p = <.05). This model accounted for 33% of variance on AIDS-Specific
anxiety. See Table 16 for a summary of the overall model. Table 17 displays the
bivariate and partial correlation coefficients for the final model.
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Table 11
Model Summary for Variable(s) Predicting AIDS-Specific

R

R2

R2ndj

Death Anxiety

.507

.257

.255

Germs Anxiety

.565

.319

Trait Anxiety

.577

.333

Step

Anxiety

AR2

F chg

p

.257

117.85

<.05

1

340

.315

.062

30.82

<.05

1

339

.327

.014

6.97

<.05

1

338

Table 17
Coefficients for Final Model Predicting AIDS-Specific

B

Death Anxiety

-3.005

p

Anxiety

t

-.335

-6.365

Germs Anxiety

.824

.263

5.194

Trait Anxiety

.365

.128

2.641

df,

df2

Discussion
The purpose of this study was to determine the influence of anxiety - both general
and specific types of anxiety - on prospective HIV testing behavior. The hypotheses
under study focused on the extent to which General anxiety, AIDS-Specific anxiety,
Blood/Injection/Injury anxiety, Germs anxiety, Hospital and X-Ray anxiety, Medications
and Pharmacist anxiety, and Death anxiety, would influence disease-status testing-related
variables: Likelihood of Being Tested for HIV and the Likelihood of Returning for the
Results of HIV Testing. Hypotheses concerning the Likelihood of Being Tested for HIV
stated that lower levels of likelihood to be tested for HIV would be associated with higher
levels of General anxiety, AIDS-Specific anxiety, Blood/Injection/Injury anxiety, Germs
anxiety, Hospital and X-Ray anxiety, Medications and Pharmacist anxiety as well as
higher levels of Death anxiety. Hypotheses concerning the Likelihood of Returning for
HIV Test Results stated that a higher likelihood of failure to return for HIV test results
would be associated with higher levels of General anxiety, AIDS-Specific anxiety,
Blood/Injection/Injury anxiety, Germs anxiety, Hospital and X-Ray anxiety, Medications
and Pharmacist anxiety, and Death anxiety.
The current study did not provide unequivocal support for the hypotheses.
Although, a higher degree of AIDS-Specific anxiety influenced the likelihood of
receiving a HIV test and a higher level of both Hospital and X-Ray anxiety influenced the
likelihood of failing to return to receive the results of a HIV test, the variance attributed
to each of these was of a low order. Once the researchers controlled for such relevant
demographic variables as gender, ethnicity, previous HIV testing history, past sexual
history, relationship status, current HIV risk, and HIV knowledge, the variance accounted
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for in the two regression equations by AIDS-Specific Anxiety and Hospital and X-Ray
Anxiety, respectively, was no longer significant and none of the variables in the study
were retained in a model. These results could potentially be due to some identified
limitations of the present study. The findings of the research were no doubt influenced by
the fact that the vast majority of the college-aged participants in the study did not report a
significantly high incidence of past HIV testing behavior or current HIV risk exposure. It
is arguable that participants with a greater risk exposure to HIV may exhibit different
HIV testing behavior, for example being more or less likely to obtain a HIV test.
Additionally, participants who have a prior history of HIV testing may be more likely to
seek out future testing considering that they have already been through the experience.
Considering the population of participants for this study, it is arguable that results were
not significant since these participants have no prior motivation or experience that guided
their HIV testing behavior. Moreover, the dependent variables chosen may have been
sub-optimal. Participants were expected to rate their HIV testing behavior based on a
hypothetical vignette, and although the researchers made an effort to present a plausible
scenario, the results very likely would have been significantly different if the participants
were assessed in vivo while actually submitting to an HIV test.
When considering the results it is also important to note the influence of (at least
within the context of the present study) extraneous variables. Past research has suggested
that specific individual characteristics, such as gender, ethnicity, and knowing someone
who is HIV positive, influence HIV testing behavior (Camlin & Chimbwete, 2003;
Hightow et al, 2003; Keenan & Keenan, 2001; Macintyre et al., 2001). The impact of
demographic and HIV-status related variables on the present study provides
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substantiation for these findings. Furthermore, the impact of factors like gender,
ethnicity, and prior HIV-testing history raises the possibility that HIV testing behavior
may be largely due to the specific characteristics and experiences of the individual rather
than a more etic or universal experience of anxiety.
It is noteworthy that the results of our exploratory analyses indicated that Death
anxiety, Germs anxiety and Trait anxiety, all added significantly to the prediction of
AIDS-Specific anxiety in a stepwise regression. Several studies have made mention of
the fear associated with HIV/ AIDS (Kaijaleena & Aavarinne, 1999; Waldner et al, 1999;
Worthington & Myers, 2003). Arguably, HIV testing behavior may be influenced by
AIDS-Specific anxiety, which, at least according to the results of the present study, may
be influenced by other specific types of anxiety. Ultimately receiving a positive HIV test
result can be interpreted by the individual who receives the results as a death sentence,
since there is currently no cure for HIV/ AIDS. When looking at HIV from this
perspective, it becomes apparent why Death anxiety may have such a significant impact
on AIDS-Specific anxiety.
Considering the dearth of past research as concerns the influence of anxiety on
HIV testing behavior, the results of this study, although limited, do provide some insight
into the role anxiety may play. The strength of the study therefore lies within its attempt
to contribute to the field as it yielded some information about the role of anxiety on HIV
testing behavior. As noted by Janssen et al. (2001) one approach to reducing HIV
incidence in the USA would be to increase the number of HIV-infected persons who are
aware of their serostatus. Possibly this study could springboard future research in the area
of HIV testing behavior. It is arguable that a greater understanding of factors impacting
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an individual's HIV testing behavior might ultimately lead to an improved testing
experience, which could decrease the vast number of individuals without knowledge of
their HIV status and ultimately may contribute to the decrease of HIV incidence.
Limitations and Future Research. As noted above, there are some possible
limitations to the present study. The population for this study consisted entirely of
college-aged individuals. Additionally, the participants were all students drawn from a
university in a relatively rural part of the southern USA. Few of these students reported a
past history of prior HIV testing, although almost three quarters of the sample reported a
past history of being sexually active. The results obtained may have been different if the
population used were either individuals who are more likely to be tested for HIV or
individuals at an elevated risk of HIV infection. A similar study may be fruitfully
repeated using a more demographically diverse population (for example a population
with older participants, more ethnically diverse participants and/ or participants with
different education level). Furthermore, it may be beneficial to repeat the study in a
population in which the participants were more likely to have been exposed to
seropositive individuals; resulting in either a higher rate of prior testing for HIV status
and/or a more likely, higher HIV risk.
Furthermore, the questions used to measure the dependent variables were derived
from a hypothetical vignette asking the participant to rate the likelihood of taking a
hypothetical HIV test. It is possible that the vignette failed to evoke a vividly imaginable
experience of being tested for HIV and thus did not engender the full range of feelings of
anxiety that would accompany the actual HIV testing experience. Ideally, future studies
may want to aim at measuring a participant's levels of anxiety, in vivo, i.e. having a
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participant complete the measure of anxiety immediately prior to receiving an actual HIV
test. Additionally, the exclusive reliance on self-report measures may have limited the
results. It is not unlikely that some of the participants may have randomly answered the
questions or may have done so in a socially desirable fashion, the latter being especially
problematic, considering that many of the questions dealt with sexual practices.
Another limitation to the present study is evident in the data analytic strategies
employed to investigate the influence of anxiety on HIV testing behavior. Since the
emphasis of the research was on the relationship between anxiety and HIV testing
behavior, regression analytic strategies were utilized to explore the influence of various
types of anxiety on HIV-testing related attitudes. However, when considering that
extraneous variables appeared to impact the interpretation of the regression models,
future research would benefit from a more exhaustive focus on the role of factors such as
age, gender, past HIV testing history, past sexual history, relationship status, and HIV
knowledge, on HIV testing behavior.
Conclusion. Despite the distinct possibility that anxiety plays a role in decisions
concerning HIV testing - for example, as a causal factor influencing failure to return for
the results of HIV testing - an extensive literature review yielded no study that
specifically examined the association between anxiety and HIV testing behavior. The
current study attempted to bridge this gap, and, although it did not yield the anticipated
results, the findings contributed to research concerning the factors that potentially
influence HIV testing behavior. Although limited, the results suggest the influence of
anxiety on HIV testing behavior. However, more noteworthy, the impact of personal
variables, such as the individual's demographics, prior HIV testing and HIV exposure
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was seen. This influence of the individual's demographics not only provides
substantiation for prior findings which explored the impact of such factors on HIV testing
behavior, but also raises the possibility that HIV testing behavior may be largely due to
the specific characteristics and experiences of the individual rather than a more etic or
universal experience of anxiety. The findings presented here may provide future
researchers with a starting point for further empirical endeavors. Considering the
limitations to this study and applying the suggestions derived from frankly addressing
these limitations, future research may indeed reveal a significant impact of anxiety on
HIV testing behavior.
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Appendix A
Dependent Variables Questions
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The following is a completely hypothetical (i.e. not true) situation.
We would like for you to vividly imagine that you have the opportunity TODAY to take
a HIV test. The test will be offered free of charge; you are assured of its anonymity,
accuracy and you can choose the HIV testing process that you prefer. In other words, you
will be given the opportunity to pick whether you want to give a blood, urine or oral
specimen; you can pick if you want to use a rapid test (results available in less than 20
minutes) or original testing (results will be available in about 2 weeks); you can choose
how you would like to receive the results (i.e. whether you will be notified by mail, have
to return to the testing facility to get the results, be contacted by the facility to set-up a
scheduled appointment to receive results, etc.)

1. On a scale of 1 to 10 with "1" being 'Not likely at all' and "10" being 'Extremely
likely', please indicate how likely you would be to have HIV testing done today under the
circumstances noted above.
1

2

3

4

5

Not likely

Somewhat

at all

likely

6

7

8

9

10
Extremely
likely

2. On a scale of 1 to 10 with "1" being 'Not likely at all' and "10" being 'Extremely
likely', please indicate how likely you would be to return to receive the results of your
HIV testing.
1

2

3

4

5

Not likely

Somewhat

at all

likely

6

7

8

9

10
Extremely
likely
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Appendix B
Demographics
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1. Age:
2. Please circle your gender
a.

Male

b. Female
3. Please indicate your ethnicity:
a. African-American
b. Asian
c.

Caucasian

d. Hispanic /Latino
e. Middle Eastern
f.

Native American

g. Pacific Islander
4. What is your current school level?
a. First year
b. Second year
c. Third year
d. Fourth Year
e. Graduate Student
5. What is the highest level of education your father completed?
a. Some High School or less
b. High School
c. Some College
d. College degree

e. Graduate degree
f.

Don't Know

What is the highest level of education your mother completed?
a. Some High School or less
b. High School
c. Some Collage
d. College degree
e. Graduate degree
f.

Don't Know
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Appendix C
Questions about Relationship history
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1. What type of relationship are you currently in?
a.

Single

b. Seeing someone
c. Steady relationship
d. Engaged
e. Married
2. How would you describe your sexual orientation?
a.

Heterosexual

b. Homosexual
c.

Bisexual

3. Have you ever been sexually active?
a. Yes
b. No
4. If Yes to question 4,
4.1 When did you first become sexually active? Age
4.2 How many sexual partners have you had (including your first and current
partner)?
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Appendix D

HIV/AIDS and HIV testing related demographics
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1. Do you personally (i.e. a close friend, relative, etc.) know someone who is currently
HIV Positive or has AIDS?
a. Yes
b. No
2. Do you know anyone who is currently HIV Positive or has AIDS?
a. Yes
b. No
3. Have you ever know someone personally (i.e. a close friend, relative, etc.) who has
passed away due to being infected with HIV/ AIDS?
a. Yes
b. No
4. Have you ever know of anyone who has passed away due to being infected with HIV/
AIDS?
a. Yes
b. No
5. Do you know your own personal HIV status?
a. Yes
b. No
6. Have you ever taken a HIV / AIDS test?
a. Yes
b. No
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Appendix E
Self-rating Anxiety Scale

90

Please carefully read each item in the list. Based on how you felt in the PAST WEEK,
INCLUDING TODAY, indicate how much you have experienced each of the following
by placing an X in the corresponding space in the column next to each item.

NONE or A
LITTLE
OF THE
TIME
1. I feel more nervous and anxious than
usual
2 . 1 feel afraid for no reason at all
3.1 get upset easily or feel panicky
4 . 1 feel like I'm falling apart and going
to pieces
5. I feel that everything is all right and
nothing bad will happen
6. My arms and legs shake and tremble
7.1 am bothered by headaches, neck
and back pains
8.1 feel weak and get tired easily
9.1 feel calm and can sit still easily
10.1 can feel my heart beating fast
11.1 am bothered by dizzy spells
12.1 have fainting spells or feel like it
13.1 can breathe in and out easily
14.1 get feelings of numbness and
tingling in my fingers, toes
15. I am bothered by stomachaches or
indigestion
16.1 have to empty my bladder often
17. My hands are usually dry and warm
18. My face gets hot and blushes
19.1 fall asleep easily and get a good
night's rest
20. I have nightmares

SOME OF
THE TIME

GOOD PART OF
THE TIME

MOST or ALL
OF THE
TIME
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Appendix F
Medical Anxiety Scale: Blood/Injection/Injury subscale
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Presented below are a series of statements relating to your attitudes toward healthcare
personnel and medical situations. Read each of the statements carefully. Beside each
statement you will find a rating scale. This scale extends from "Strongly Disagree" to
"Strongly Agree". The six points of the scale are as follows: "1" is Strongly

Disagree;

"2" is Somewhat Disagree; "3" indicates slight disagreement with the statement; "4" is
Slightly Agree, "5" is Somewhat Agree, or, "6" is Strongly Agree. For each statement,
check or fill in the circle that best indicates your attitude. Please answer all questions
thoughtfully.
1. Needles and injections terrify me.

©
Strongly
Disagree
2.

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

Having blood being drawn from my arm makes me woozy and/or nauseous.

©
Strongly
Disagree

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

3. Needles and shots don't cause me any sense of alarm.

©
Strongly
Disagree
4.

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

I feel faint when I have blood drawn.

©
Strongly
Disagree

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

5. The period of waiting for the results of medical tests is very anxiety provoking.
©
©
©
©
©
©
Strongly
Disagree

Somewhat
Disagree

Slightly
Disagree

Slightly
Agree

Somewhat
Agree

Strongly
Agree
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6.

I don't mind having blood drawn.

Strongly
Disagree
7,

Somewhat
Disagree

Slightly
Disagree

Slightly
Agree

Somewhat
Agree

Strongly
Agree

I fear visits to the doctor because I know there may be a needle or a blood test
involved.

©
Strongly
Disagree

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree
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Appendix G
Medical Anxiety Scale: Germs subscale
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Presented below are a series of statements relating to your attitudes toward healthcare
personnel and medical situations. Read each of the statements carefully. Beside each
statement you will find a rating scale. This scale extends from "Strongly Disagree" to
"Strongly Agree". The six points of the scale are as follows: "1" is Strongly Disagrees
"2" is Somewhat Disagree; "3" indicates slight disagreement with the statement; "4" is
Slightly Agree, "5" is Somewhat Agree; or, "6" is Strongly Agree. For each statement,
check or fill in the circle that best indicates your attitude. Please answer all questions
thoughtfully.
1. Doctor's waiting rooms are filled with germs from all the sick people who pass
through them.

©
Strongly
Disagree
2.

Strongly
Disagree

Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

Somewhat
Disagree

Slightly
Disagree

Slightly
Agree

Somewhat
Agree

Strongly
Agree

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

I'm made anxious by the fact that they may not sterilize the medical instruments at
my doctor's office after every use.
©
©
®
©
©
©

Strongly
Disagree
5.

Slightly
Disagree

©

When I hear about a serious infectious disease, I worry that I'll catch it.

©

4.

Somewhat
Disagree

©

I intentionally avoid being around sick people to keep from getting ill myself.
©
©
©
©
©
©

Strongly
Disagree
3.

©

Somewhat
Disagree

Slightly
Disagree

Slightly
Agree

Somewhat
Agree

Strongly
Agree

I'm afraid that the instruments used in a doctor's office aren't disinfected after every
examination.
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©
Strongly
Disagree
6.

Strongly
Disagree

Strongly
Disagree

Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

Germs are transmitted between patients because doctors and nurses don't sterilize the
medical instruments they use.

©
Strongly
Disagree
9.

Slightly
Disagree

©

I get frightened for my health when I hear news stories about major current health
risks like the AIDS virus.

©

8.

Somewhat
Disagree

©

I'm disgusted by all the germs that are on the medical instruments in my doctor's
examination room.

©

7.

©

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

Because they're filled with "sick" people, I'm afraid I'll catch something from sitting
in a doctor's examination room.

©
Strongly
Disagree

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

10. The thought of all the germs in a doctor's office make me nervous.

©
Strongly
Disagree

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree
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Appendix H
Medical Anxiety Scale: Hospital & X-Ray subscale
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Presented below are a series of statements relating to your attitudes toward healthcare
personnel and medical situations. Read each of the statements carefully. Beside each
statement you will find a rating scale. This scale extends from "Strongly Disagree" to
"Strongly Agree". The six points of the scale are as follows: "1" is Strongly

Disagree;

"2" is Somewhat Disagree; "3" indicates slight disagreement with the statement; "4" is
Slightly Agree] "5" is Somewhat Agree, or, "6" is Strongly Agree. For each statement,
check or fill in the circle that best indicates your attitude. Please answer all questions
thoughtfully.
1. Everything about a hospital - the colors, the long corridors, the smells - makes me
anxious.

©
Strongly
Disagree
2.

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

It scares me to be in a hospital that's filled with sick people and all those germs.
©
©
©
©
©
©

Strongly
Disagree

Somewhat
Disagree

Slightly
Disagree

Slightly
Agree

Somewhat
Agree

Strongly
Agree

3. The level of cleanliness in hospitals is generally very high.

©
Strongly
Disagree
4.

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

I get anxious even visiting a hospital.

©
Strongly
Disagree

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

5. Hospitals are full of germs and bacteria, many of which can make you very ill.
©
©
©
©
©
©
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Strongly
Disagree
6.

Somewhat
Disagree

Slightly
Disagree

Slightly
Agree

Somewhat
Agree

Strongly
Agree

If I had a major surgery done, I'd be afraid they would leave something inside me,
like a surgical tool or sponge.
©
©
©
.©
©
©

Strongly
Disagree

Somewhat
Disagree

Slightly
Disagree

Slightly
Agree

Somewhat
Agree

Strongly
Agree

7. Hospitals make me anxious because when you're a patient you're really not in
control of your life.

©
Strongly
Disagree

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

8. Hospitals are associated with severe illness or death.

©
Strongly
Disagree

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

9. The idea of being a patient in a hospital scares me because I probably wouldn't
clearly understand a lot of what was going on with my treatment.

Strongly
Disagree

Somewhat
Disagree

Slightly
Disagree

Slightly
Agree

Somewhat
Agree

Strongly
Agree

10. Hospitals may harm as many people as they cure.

©
Strongly
Disagree

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

11. I have (or would have) no real problem being a hospital patient.

©
Strongly
Disagree

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

12. I'm frightened that X-Rays and the other ways they use to take images (like MRIs
and CAT scans) might cause permanent physical damage.
©
©
©
©
©
©
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Strongly
Disagree

Somewhat
Disagree

Slightly
Disagree

Slightly
Agree

Somewhat
Agree

Strongly
Agree

13. Whenever I get an X-Ray (or an MRI or CAT scan), I visualize them finding
something disturbing like a tumor.
©
©
©
©
©
©
Strongly
Disagree

Somewhat
Disagree

Slightly
Disagree

Slightly
Agree

Somewhat
Agree

Strongly
Agree

14. If I had to get an MRI or CT scan - where I was put into an enclosed space to have a
picture taken - I would very likely have an anxiety attack.

©
Strongly
Disagree

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree
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Appendix I

Medical Anxiety Scale: Medications and Pharmacist subscale
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Presented below are a series of statements relating to your attitudes toward healthcare
personnel and medical situations. Read each of the statements carefully. Beside each
statement you will find a rating scale. This scale extends from "Strongly Disagree" to
"Strongly Agree". The six points of the scale are as follows: "1" is Strongly

Disagree;

"2" is Somewhat Disagree; "3" indicates slight disagreement with the statement; "4" is
Slightly Agree; "5" is Somewhat Agree', or, "6" is Strongly Agree. For each statement,
check or fill in the circle that best indicates your attitude. Please answer all questions
thoughtfully.
1. The act of taking medication generally doesn't cause me any anxiety.

©
Strongly
Disagree
2.

Strongly
Disagree

Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

Somewhat
Disagree

Slightly
Disagree

Slightly
Agree

Somewhat
Agree

Strongly
Agree

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

I'm afraid of taking vaccines because I may react badly to them.

©
Strongly
Disagree
5.

Slightly
Disagree

©

I dread the idea of having to take any medication.

©

4.

Somewhat
Disagree

®

I'm always afraid that either the doctor or the pharmacist has made a mistake of some
kind when I have to take medication.
©
©
©
©
©
©

Strongly
Disagree
3.

©

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

Taking any medication at all makes me anxious.

©
Somewhat
Agree

©
Strongly
Agree
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©
Strongly
Disagree
6.

Strongly
Disagree

Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

Somewhat
Disagree

Slightly
Disagree

Slightly
Agree

Somewhat
Agree

Strongly
Agree

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

I'm afraid that the pharmacist will misread my doctor's handwriting on a
prescription.

©
Strongly
Disagree
9.

Slightly
Disagree

©

I generally experience no anxiety when I have to take medications.

©

8.

Somewhat
Disagree

©

I get nervous about all that could go wrong when I take any new medication.
©
©
©
©
©
©

Strongly
Disagree
7.

©

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

I'm nervous that my pharmacist will fill my prescription incorrectly and harm me as a
result.

©

„._.©

Strongly
Disagree

Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree

10. I feel safe taking the medications I've received from pharmacists.

©
Strongly
Disagree

©
Somewhat
Disagree

©
Slightly
Disagree

©
Slightly
Agree

©
Somewhat
Agree

©
Strongly
Agree
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Appendix J
Death Anxiety Scale
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Please circle true or false
1. I am very much afraid to die.

True

False

2. The thought of death seldom enters my mind.

True

False

3. It doesn't make me nervous when people talk about death.

True

False

4. I dread to think about having to have an operation.

True

False

5. I am not at all afraid to die.

True

False

6.1 am not particularly afraid of getting cancer.

True

False

7. The thought of death never bothers me.

True

False

8.1 am often distressed by the way time flies so very rapidly.

True

False

9. I fear dying a painful death.

True

False

10. The subject of life after death troubles me greatly.

True

False

11.1 am really scared of having a heart attack.

True

False

12.1 often think about how short life really is.

True

False

13. I shudder when I hear people talk about a World War III.

True

False

14. The sight of a dead body is horrifying to me.

True

False

15.1 feel that the future holds nothing for me to fear.

True

False
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Appendix K
Multidimensional Aids Anxiety Questionnaire
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The items listed below refer to feelings and reactions that people may experience about
the disease AIDS (Acquired Immune Deficiency Syndrome). As such, there are no right
or wrong answers, only the individual reactions that people have. We are interested in
how typical these feelings and behaviors are of you. To provide your responses, use the
following scale to indicate how characteristic the following statements are of you:
1 = Not at all characteristic of me.
2 = Slightly characteristic of me.
3 = Somewhat characteristic of me.
4 = Moderately characteristic of me.
5 = Very characteristic of me.
NOTE: Remember to respond to all items, even if you are not completely sure.
Also, please be honest in responding to these statements.

Thinking about AIDS makes me feel anxious.

__.©

©

©

©

I sometimes find it hard to discuss issues dealing with AIDS

© - - -

__.©

®

©

©

I feel tense when I think about the threat of AIDS

© - - -

__.©

®

©

©

I feel quite anxious about the epidemic of AIDS

© - - -

__.©

®

©

©

I feel scared about AIDS when I think about sexual relationships

© - - -

___©

®

©

©

I'm afraid of getting AIDS

© - - -

®

©

©

___©

®

©

©

I have trouble talking about AIDS with an intimate partner
I feel frustrated when I realize the threat of AIDS

© - - -

._.©

®

©

©

The disease AIDS makes me feel nervous and anxious

© - - -

__.©

®

©

©

I feel scared when I think about catching AIDS from a sexual
partner

© - - -

- _ - ©

©

©

©

I'm not worried about getting AIDS

© - - -

___©

©

©

©

I would feel shy discussing AIDS with an intimate partner

© - - -

___©

®

©

©

My heart beats fast with anxiety when I think about AIDS

© - - -

___©

®

©

©

I feel anxious when I talk about AIDS with people

© - - -

_._©

®

©

©

- . . ©

©

©

©

Because of AIDS. I feel nervous about initiating sexual relations
All these discussions of AIDS leaves me feeling a bit alarmed

© - - -

___©

©

©

©

I would not find it hard to discuss AIDS with an intimate partner

© - - -

___©

©

©

©
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AIDS makes me feel jittery about having sex with someone

CD

©

©

©

©

I feel uncomfortable when discussing AIDS

®

©

©

©

©

I sometimes worry that one of my past sexual partners may have
had AIDS

©

©

©

©

©

Thinking about catching AIDS leaves me feeling concerned

©

©

®

©

©

related concerns

©

©

®

©

©

The issue of AIDS is a very stressful experience for me

©

©

©

©

©

I feel nervous when I discuss AIDS with another person

©

©

©

©

©

The threat of getting AIDS makes me feel uneasy about sex
I worry about what I should do about AIDS

©
©

©
©

©
©

©
©

©
©

Anxiety about AIDS is beginning to affect my personal
relationships

©

©

©

©

©

In general, the media attention on AIDS makes me feel restless

©

©

©

©

©

I have feelings of worry when I think about AIDS

©

©

©

©

©

Were I to have sexual relations, I would worry about getting
AIDS

©

©

®

©

©

All this recent media attention about AIDS leaves me feeling on
edge

©

©

®

©

©

AIDS does not influence my willingness to engage in sexual
relationships

©

©

®

©

©

When I think about AIDS, I feel tense

©

®

©

©

©

I am more anxious than most people are about the disease AIDS

©

®

®

©

©

If I were to have sex with someone, I would worry about AIDS
I'm pretty indifferent to the idea of catching AIDS

©
©

©
©

©
©

©
©

©
©

I would hesitate o involve myself in a sexual relationship
because of AIDS

©

©

©

©

©

When talking about AIDS with someone, I feel jumpy and highstrung

©

©

®

©

©

I become really frightened when I think about the threat of
AIDS

©

©

©

©

©

The fear of AIDS makes me feel nervous about engaging in sex

©

©

®

©

©

The increased chances of being infected with AIDS leaves me
feeling troubled

©

©

®

©

©

Because of AIDS, I feel too nervous to start a new sexual
relationship

©

©

©

©

©

The spread of AIDS is causing me to feel quite a bit of stress

©

©

©

©

©

I worry that AIDS may directly influence my life

©

©

®

©

©

I would not hesitate to ask a former sex partner about AIDS-
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I had a better attitude towards sex before the AIDS epidemic

©

©

©

©

©

AIDS

©

©

©

©

©

The discussion of AIDS makes me feel uncomfortable

©

©

©

©

©

All this talk about AIDS has left me feeling strained and tense

©

©

©

©

©

I'm concerned that I might be carrying the AIDS virus
I feel nervous when I think that a past sexual partner could have
given me AIDS

©

©

©

©

©

©

©

©

©

©

I get pretty upset when I think about the possibility of catching
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Appendix L
HIV risk assessment

Ill

Since your last HIV test (if ever), have you...
1. .. .injected drugs and shared equipment (e.g., needles, syringes,
cotton, water) with others?

Yes

No

Yes

No

Yes

No

4. .. .been diagnosed or treated for an STD, hepatitis, or tuberculosis?

Yes

No

5. .. .had a fever or illness of unknown cause?

Yes

No

6. .. .been told you have an infection related to a 'weak immune system'? Yes

No

2. .. .had unprotected intercourse with someone that you think might
be infected (e.g., a partner who injected drugs, has been diagnosed
or treated for a sexually transmitted disease [STD] or hepatitis, has
had multiple or anonymous sex partners, or has exchanged sex for
drugs or money)?
3. .. .had unprotected vaginal or anal intercourse with more than one sex
partner?
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Appendix M
HIV Knowledge Questionnaire
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Please circle whether the following statements are True or False.
1. Coughing and sneezing DO NOT spread HIV

True

False

2. A person can get HIV by sharing a glass of water with someone who has HIV

True

False

True

False

True

False

True

False

True

False

True

False

True

False

True

False

True

False

True

False

True

False

True

False

True

False

True

False

True

False

True

False

3. Pulling out the penis before a man climaxes/cums keeps a woman from
getting HIV during sex
4. A woman can get HIV if she has anal sex with a man
5. Showering, or washing one's genitals/ private parts, after sex keeps
a person from getting HIV
6. All pregnant women infected with HIV will have babies born with AIDS
7.People who have been infected with HIV quickly show serious signs of
being infected
8. There is a vaccine that can stop adults from getting HIV
9. People are likely to get HIV by deep kissing, putting their tongue in
their partner's mouth, if their partner has HIV
10. A woman cannot get HIV if she has sex during her period
11. There is a female condom that can help decrease a woman's chance
of getting HIV
12. A natural skin condom works better against HIV than does a latex
condom
13. A person will NOT get HIV if she or he is taking antibiotics
14. Having sex with more than one partner can increase a person's chance
of being infected with HIV
15. Taking a test for HIV one week after having sex will tell a person if
she or he has HIV
16. A person can get HIV by sitting in a hot tub or a swimming pool with
a person who has HIV
17. A person can get HIV from oral sex
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18. Using Vaseline or baby oil with condoms lowers the chance of getting
HIV

True

False
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Appendix N
Human Subjects Review Board Approval
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WESTERN KENTUCKY UNIVERSITY
Human Subjects Review Board
Office of Sponsored Programs
301 Potter Hall
270-745-4652; Fax 270-745-4211
E-mail: Sean. Rubino@wku.edu

In future correspondence please refer to HS07-129, February 7, 2007
Ilze Nix
c/o Dr. Phil Pegg
Department of Psychology
WKU
Dear Ilze:
Your revision to your research project, "Personal Medical Questionnaire," was reviewed by the
HSRB and it has been determined that risks to subjects are: (1) minimized and reasonable; and
that (2) research procedures are consistent with a sound research design and do not expose the
subjects to unnecessary risk. Reviewers determined that: (1) benefits to subjects are considered
along with the importance of the topic and that outcomes are reasonable; (2) selection of subjects
is equitable; and (3) the purposes of the research and the research setting is amenable to subjects'
welfare and producing desired outcomes; that indications of coercion or prejudice are absent, and
that participation
is clearly voluntary.
In addition, the IRB found that you need to orient participants as follows: (1) signed informed
consent is required; (2) Provision is made for collecting, using and storing data in a manner that
protects the safety and privacy of the subjects and the confidentiality of the data. (3) Appropriate
safeguards are included to protect the rights and welfare of the subjects.
This project is therefore approved at the Expedited Review Level until May 31, 2007.
Please note that the institution is not responsible for any actions regarding this protocol before
approval. If you expand the project at a later date to use other instruments please re-apply. Copies
of your request for human subjects review, your application, and this approval, are maintained in
the Office of Sponsored Programs at the above address. Please report any changes to this
approved protocol to this office. Also, please use the stamped Informed Consent documents that
are included with this letter. A Continuing Review protocol will be sent to you in the future to
determine the status of the project.
Sincerely,

Sean Rubino, M.P.A.
Compliance Manager
Office of Sponsored Programs
Western Kentucky University
cc: HS file number Nix HS07-129
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Appendix O
Informed Consent
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You are being asked to participate in a study that will evaluate your attitudes and
behavior patterns with relation to medical behavior. Please read the following material
thoroughly. It describes the purpose of the study in brief, the procedure to be used, risks
and benefits of your participation, and what will be done to the information that is being
collected from you. This study is being conducted through Western Kentucky
University. The University requires that you give your signed agreement to participate in
this project.
The investigator will explain to you the purpose of the project, the procedures to
be used, and the potential benefits and possible risks of participation. You may ask her or
him any questions you have to help you understand the project. A basic explanation of
the project is provided below. Please read this explanation and discuss with the researcher
any questions you may have.
If you then decide to participate in the project, please sign on the last page of this
form in the presence of the person who explained the project to you. By signing this
form, you are indicating that you are aware of the risks and benefits of this project.
This project is completely voluntary. You do not have to participate under any
circumstance.
1. PROJECT TITLE
Personal Medical Behavior Questionnaire
2. PRINCIPAL INVESTIGATOR
Ilze Nix, graduate student, (ilze.nix@wku.edu)
Dr. Phil Pegg, faculty supervisor, (phil.pegg@wku.edu)
Western Kentucky University, Department of Psychology, (270) 745-4417
3. NATURE AND PURPOSE OF THE PROJECT
The purpose of this study is to evaluate personal health practices and attitudes.
4. EXPLANATION OF PROCEDURES
You will be asked to complete a questionnaire regarding demographic
information (i.e. questions about yourself) as well various questionnaires designed to
assess your personal health practices and behaviors. This session will take about 60
minutes.
5. DISCOMFORT AND RISKS
We are looking for your honest answers to these surveys. There is minimal risk
that the information on the questionnaires may cause any psychological distress. If this
occurs, please inform your researcher.
6. BENEFITS
As a participant in the study, you will be contributing to science and helping
researchers gain more knowledge that will foster a better understanding about the various
attitudes and behavior patterns people have with relation to medical behavior. If you are a
student of Western Kentucky University an additional benefit to you is that extra credit
for participation may be granted or the involvement in this study might fulfill the research

119

requirements of Introduction to Psychology, all at the discretion of your class professors.
No other inducements will be offered.
7. CONFIDENTIALITY
You will be asked to choose your own unique pseudonym that you will need to
indicate on your questionnaire packet or at the conclusion of the Internet survey. This
pseudonym will be the only 'identifying' information directly provided as part of the
packet. You will be required to provide the information needed (i.e. your name and WKU
ID) and your chosen pseudonym on along with a signed copy of the Informed Consent
page, regardless of whether you complete the study in paper-pencil format or online. The
informed consent page and pseudonym information will be kept separate from the
collected response and will only be used to assign extra credit. Furthermore, each
participant will be assigned a unique identification number by the researchers. This
identification number (unique to each of the participants) will be used to make sure that
no duplicate data will be entered in the database.
Your identity and the identity of all participants will never be revealed in any
published or oral presentation of the results of this project. All data from this project will
be kept confidential to the extent of the law. All data that is published or presented will
be done in a way that does not reveal the identity of a participant.
8. REFUSAL/WITHDRAWAL
Refusal to participate in this study will have no effect on any future services
that you may be entitled to from the University. Anyone who agrees to participate in this
study is free to withdraw from the study at any time with no penalty.
You understand also that it is not possible to identify all potential risks in an
experimental procedure, and you believe that reasonable safeguards have been taken to
minimize both the known and potential but unknown risks.

Pseudonym:

Signature of Participant

Date

Witness

Date

THE DATED APPROVAL ON THIS CONSENT FORM INDICATES THAT
PROJECT HAS BEEN REVIEWED AND APPROVED BY THE WESTERN KENTUCKY
UNIVERSITY HUMAN SUBJECTS REVIEW BOARD
Dr. Phillip E. Meyers, Human Protections Administrator
TELEPHONE: (270) 745-4652
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Appendix P
Debriefing Form
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We would like to thank you for your participation in this research. Your contribution will
add to the knowledge base concerning the HIV testing behavior. A better understanding
of this could lead to an improvement in the services provided to you and other
participants, and might lead to better advice and support offered to individuals when they
participate in HIV testing. Furthermore, the community at large can benefit as a clearer
understanding of HIV testing behavior may lead to an increase in the number of
individuals who choose to become aware of their HIV status by taking a HIV test.
If you would like to determine your own HIV status, following is a list of resources
available to you.
1. WKU Health Services
o 1906 College Heights Blvd. #8400; Bowling Green, Kentucky; 42101
o Phone:(270)745-5641
o Operating Hours: Monday - Thursday 8am-4:30pm / Friday 10am4:30pm
o Email: wkuhealthservices@wku.edu
2. Barren River District Health Department
o
o

1109 State St; PO Box 1157; Bowling Green, KY; 42102
Phone: (270) 781-8039

3. Center for Disease Control
o Phone: CDC-INFO 24 Hours/Day at I-8OO-CDC-INFO (232-4636), 1888-232-6348 (TTY), in English, en Espanol.
o Website: http://www.hivtcst.org/
If you would like more information about HIV/ AIDS, following is a list of
credible websites available to you.
1. http://www.cdc.gov/hiv/
2. http://chfs.ky.gov/dph/epi/1iivaids.htm
3. http://www.aids.gov/
4. http://www.aidsinfo,nih.gov/

In the event that the information on the questionnaires may have caused you any
psychological distress please inform the researcher. Additionally, services are available
through Western Kentucky University that you can utilize in such an event. Please
contact the Counseling and Testing Center at 409 Potter Hall, 1906; College Heights
Blvd. #1102; Bowling Green KY; 42101.
Phone: (270) 745-3159
Email: counseling@wku.edu

